Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0 
Version  date 8/8/2018  
Page  1 of 67 FULL  PROTOCOL  TITLE  
Topiramate  as a disease  modifying  therapy  for Cryptogenic  Sensory  Peripheral  Neuropathy  in 
Metabolic  Syndrome  (CSPN)   
 
Protocol  Version:  8.0 
Protocol  Date:  8/8/2018  
 
SHORT  PROTOCOL  TITLE  
The TopCSPN  Study  / Topiramate  as a Disease  Modifying  Therapy  for CSPN  
 
Protocol  Principal  Investigator  (PPI);  
A. Gordon  Smith,  M.D.  
Professor  and Chair  of Neurology  
VCU  Department  of Neurology  
Virginia  Commonwealth  University  
 
Suppor ted by: 
The National  Institute  of Neurological  Disorders  and Stroke  (NINDS)  
U01NS095388  
  
Sponsor  of IND/IDE:  
IND Exempt  (IND 125823)  
 
 
 
 
 
 
 
 
 
The information  contained  herein  is confidential  and proprietary  in nature,  and will not be 
disclosed  to any third party  without  written  approval  of authorized  designee.   This document  may 
be disclosed  to the appropriate  institutional  review  boards  or to duly authorized  representatives  
of the US Food  and Drug  Administration  or a national  regulatory  authority  unde r the condition  that 
they maintain  confidentiality.  
  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  2 of 67 TABLE  OF CONTENTS  
 
INVESTIGATOR  AGREEMENT ................................ ................................ ................................ .. 5 
1. STUDY  OBJECTIVES  ................................ ................................ ................................ ...........  9 
1.1. Primary  Objectives  ................................ ................................ ................................ ...........  9 
1.2. Secondary  Objectives  ................................ ................................ ................................ ..... 10 
2. BACKGROUND  ................................ ................................ ................................ ..................  10 
2.1. Target  Population  ................................ ................................ ................................ ...........  10 
2.2. Study  Timeline  ................................ ................................ ................................ ...............  11 
2.3. Rationale ................................ ................................ ................................ .........................  11 
2.4. Supporting  Data ................................ ................................ ................................ ..............  12 
3. STUDY  DESIGN ................................ ................................ ................................ ..................  14 
4. SELECTION  AND  ENROLLMENT  OF SUBJECTS  ................................ .........................  15 
4.1. Inclusion  Criteria  ................................ ................................ ................................ ............  15 
4.2. Exclusion  Criteria  ................................ ................................ ................................ ...........  16 
4.3. Subject  Withdrawal  Criteria  ................................ ................................ ...........................  17 
4.4. Study  Enrollment  Procedures  ................................ ................................ .........................  18 
4.4.1.  Subject  Recruitment  and Retention  ................................ ................................ ........  18 
4.4.2.  Screening  Logs ................................ ................................ ................................ ........  18 
4.4.3.  Informed  Consent ................................ ................................ ................................ .... 19 
4.4.4.  Assent  ................................ ................................ ................................ ......................  19 
4.4.5.  Randomization/Treatment  Assignment  ................................ ................................ .. 19 
5. STUDY  INTERVENTIONS/  STUDY  DRUG  ................................ ................................ ..... 20 
5.1. Study  Drug  and Dose  Selection  ................................ ................................ .....................  20 
5.2. Dose  selection  ................................ ................................ ................................ ................  20 
5.3. Formulation  and Packaging  ................................ ................................ ............................  20 
5.3.1.  Supplies  and Dispensatio n ................................ ................................ ......................  21 
5.3.2.  Titration  Schedule  and Dose  Adjustments  ................................ ..............................  21 
5.4. Concomitant  Interventions  ................................ ................................ .............................  22 
5.4.1.  Prohibited  Medications/Interventions  ................................ ................................ ..... 22 
5.5. Subject  Compliance ................................ ................................ ................................ ........  23 
6. STUDY  PROCEDURES  ................................ ................................ ................................ ...... 23 
6.1. Schedule  of Assessments  ................................ ................................ ...............................  23 
6.2. Visit  01 Screening  (Day  -30 to 0) ................................ ................................ ..................  23 
6.3. Re-screening  ................................ ................................ ................................ ...................  24 
6.4. Visit  02 Baseline  (Day  0) ................................ ................................ ...............................  25 
6.5. Visit  03 Week  16 (± 7 days)  ................................ ................................ ...........................  26 
6.6. Visit  04 Week  32 (± 7 days)  ................................ ................................ ...........................  27 
6.7. Visit  05 Week  48 (± 7 days)  ................................ ................................ ...........................  28 
6.8. Visit  06 Week  64 (± 7 days)  ................................ ................................ ...........................  28 
6.9. Visit  07 Week  80 (± 7 days)  ................................ ................................ ...........................  29 
6.10.  Visit  08 Week  96 Termination  (± 7 days)  ................................ ................................ ...... 30 
6.11.  Visit  09 Safety  Assessment  ................................ ................................ ............................  31 
6.12.  Early  Termination  Visit  (< 30 ± 7 days)  ................................ ................................ ........  31 
6.13.  Early  Termination  and Premature  Withdrawal  ................................ ..............................  32 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  3 of 67 6.13.1.  Premature  Drug  Discontinuation  ................................ ................................ ............  33 
6.13.2.  Restarting  Study  Drug  after Premature  Drug  Discontinuation  ...............................  33 
6.13.3.  Missed  Doses  ................................ ................................ ................................ ..........  33 
6.13.4.  On Study/Off -Intervention  Evaluations  ................................ ................................ .. 33 
6.14.  Off-Study  Require ments  ................................ ................................ ................................  34 
6.15.  Pregnancy  ................................ ................................ ................................ .......................  34 
6.16.  Diabetes  ................................ ................................ ................................ ..........................  34 
7. SPECIAL  INSTRUCTIONS  AND  DEFINITIONS  OF EVALUATIONS  ...................  34 
7.1.1.  Informed  Consent ................................ ................................ ................................ .... 34 
7.1.2.  Protocol  Violations  ................................ ................................ ................................ . 34 
7.1.3.  Medical  History  ................................ ................................ ................................ ...... 35 
7.1.4.  Concomitant  Medications/Treatments  ................................ ................................ .... 35 
7.1.5.  Physical  Examination ................................ ................................ ..............................  35 
7.1.6.  Vital  Signs  ................................ ................................ ................................ ...............  35 
7.1.7.  Waist  Circumference  ................................ ................................ ..............................  35 
7.1.8.  Electrocardiogram  (ECG)  ................................ ................................ .......................  35 
7.1.9.  Neuropathy  Symptom  Assessment  ................................ ................................ .........  36 
7.1.10.  Utah  Early  Neuropathy  Scale  (UENS)  ................................ ................................ ... 36 
7.1.11.  Functional  and Mobility  Testing  ................................ ................................ .............  36 
7.1.12.  Laboratory  Evaluations  ................................ ................................ .............................  36 
7.1.14.  Skin Biopsy  ................................ ................................ ................................ ...............  38 
7.1.14.1.  Distal  Thigh  Skin Biopsy  ................................ ................................ ................  39 
7.1.15.  Columbia -Suicide  Severity  Rating  Scale  (C-SSRS)  ................................ ...............  39 
7.1.16.  The Norfolk  Quality  of Life – Diabetic  Neuropathy  (NQOL -DN) Scale  ...............  39 
7.1.17.  The Rapid  Assessment  of Physical  Activity  (RAPA)  Survey  ................................  39 
7.1.18.  Subject  Adherence  Assessments  ................................ ................................ .............  40 
7.1.19  Optional  Tissue  Banking ................................ ................................ ............................  40 
8. MANAGEMENT  OF ADVERSE  EVENTS  ................................ ................................ ........  40 
8.1. Pregnancy  ................................ ................................ ................................ .......................  42 
9. PROTOCOL  AMENDMENTS  AND  STUDY  TERMINATION  ................................ ....... 42 
10. STATISTICAL  CONSIDERATIONS ................................ ................................ ...............  42 
10.1.  Outcomes  ................................ ................................ ................................ ........................  47 
10.1.1.  Primary  Outcome  (including  definition)  ................................ ................................ . 47 
10.1.2.  Secondary  Outcome(s)  ................................ ................................ ............................  48 
10.1.3.  Exploratory  Outcomes  ................................ ................................ ............................  49 
10.2.  Data  Monitoring  ................................ ................................ ................................ .............  49 
11. DATA  COLLECTION,  SITE  MONITORING,  AND  ADVERSE  EXPERIENCE  
REPORTING  ................................ ................................ ................................ ................................  50 
11.1.  Data  Management  ................................ ................................ ................................ ..........  50 
11.1.1.  Registration  ................................ ................................ ................................ .............  50 
11.1.2.  Data  Entry  ................................ ................................ ................................ ...............  51 
11.2.  Role  of Data  Management ................................ ................................ ..............................  51 
11.3.  Quality  Assurance  ................................ ................................ ................................ ..........  51 
11.3.1.  Development  of Monitoring  Plan ................................ ................................ ...........  51 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  4 of 67 11.3.2.  Site Monitoring  Visits  ................................ ................................ .............................  52 
11.3.3.  Laboratory  Data  Flow  ................................ ................................ .............................  52 
11.4.  Adverse  Experience  Reporting ................................ ................................ .......................  52 
11.4.1.  Definitions  of Adverse  Events,  Suspected  Adverse  Drug  Reactions  & Serious  
Adverse  Events  ................................ ................................ ................................ .....................  54 
11.4.1.1.  Adverse  Event  Collection  and Reporting  ................................ ..............................  54 
11.4.1.2.  Serious  Adverse  Events  ................................ ................................ ..........................  55 
11.4.2.  Assessment  and Recording  of Adverse  Events  ................................ ..................  56 
12. HUMAN  SUBJECTS  ................................ ................................ ................................ ........  58 
12.1.  Institutional  Review  Board  (IRB)  Review  and Informed  Consent  ................................  58 
12.2.  Subject  Confidentiality  ................................ ................................ ................................ ... 58 
12.3.  Study  Modification/Discontinuation  ................................ ................................ ..............  59 
13. PUBLICATION  OF RESEARCH  FINDINGS  ................................ ................................ . 59 
14. REFERENCES  ................................ ................................ ................................ ..................  59 
15. Appendix  A ................................ ................................ ................................ ........................  66 
 
 
  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  5 of 67 INVESTIGATOR  AGREEMENT  
 
I have  read the foregoing  protocol  [version  8.0, dated  8/8/2018 ] and agree  to conduct  the study  
as described  herein.  
By signing  the protocol,  the Investigator  agrees  to keep  all information  provided  by the 
NeuroNEXT  Network  in strict  confidence  and to request  the same  from his/her  staff and the 
Institu tional  Review  Board.  Study  documents  provided  by the NeuroNEXT  Network  will be stored  
appropriately  to ensure  their confidentiality.  The Investigator  should  not disclose  such  information  
to others  without  authorization,  except  to the extent  necessary  to conduct  the study.   
 
 
 
 
 
______________________________________  _______________________  
Investigator  Signature  Date  
______________________________________  
Print  Investigator’s  Name  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  6 of 67 SIGNATURE  PAGE  
Study  Number:   
NN108  
 
Principal  Investigator  Approval:  
 
 Signature:                                                                                    Date:  
 Name:  A. Gordon  Smith,  MD   
 
 
NeuroNEXT  Clinical  Coordinating  Center  Approval:  
 
Signature:                                                                                    Date:  
 Name:  Merit  Cudkowicz,  MD   
 
 
NeuroNEXT  Data  Coordinating  Center  Approval:  
 
Signature:                                                                                    Date:  
Name:  Christopher  Coffey,  PhD    
 
 
 
 
 
 
 
 
 
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  7 of 67  
LIST  OF ACRONYMS,  ABBREVIATIONS,  AND  DEFINITIONS  OF TERMS   
 
6MWT    6 Minute  Walk  Test 
ABC   Activities -specific  Balance  Confidence  
AE   Adverse  Event  
ADA   American  Diabetes  Association  
BMI   Body  Mass  Index  
BMP    Basic  Metabolic  Panel  
BPI-DN  Brief Pain Inventory  – Diabetic  Neuropathy  
CCC    Clinical  Coordination  Center  
CDE    Common  Data  Elements  
CFR   Code  of Federal  Regulations  
CIRB     Central  Institutional  Review  Board  
CRF   Case  report  form 
CS   Clinically  Significant  
CSPN    Cryptogenic  Sens ory Peripheral  Neuropathy   
CSS PI  Clinical  Study  Site PI 
C-SSRS   Columbia -Suicide  Severity  Rating  Scale  
DCC    Data  Coordination  Center  
DOR    Delegation  of Responsibility  
DPP    Diabetes  Prevention  Program  
DM   Data  Management  
DSMB    Data  Safety  Monitoring  Board  
ECG    Electrocardiogram  
eCRF    Electronic  Case  Report  Form  
EDC    Electronic  data capture  
FDA       Food  and Drug  Administration  
GCP    Good  Clinical  Practice  
HIPAA    Health  Insurance  Portability  and Accountability  Act 
ICF   Informed  Consent  Form  
ICH   International  Conference  on Harmonization   
IENFD     Intraepidermal  Nerve  Fiber  Density  
IGT    Impaired  Glucose  Tolerance  
IGTN     Impaired  Glucose  Tolerance  Neuropathy  
IMM   Independent  Medical  Monitor  
IRB   Institutional  Review  Board  
IVRS    Interactive  Voice Response  System  
IWRS    Interactive  Web Response  System  
MedDRA   Medical  Dictionary  for Regulatory  Activities  
NCS    Nerve  Conduction  Studies  
NCS    Not Clinically  Significant  
NINDS    National  Institute  of Neurological  Disorders  and Stroke  
NQOL -DN  Norfol k Quality  of Life – Diabetic  Neuropathy  
NIS-LL   Neuropathy  Impairment  Scale  Lower  Limb  
NTSS -6  Neuropathy  Total  Symptom  Score  – 6 
PPI   Protocol  Principal  Investigator  
PLP   Paraformaldehyde  Lysine  Phosphate  
PSC   Protocol  Steering  Committee  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  8 of 67 QOL      Quality  of Life 
QUICKI   Quantitative  Insulin  Sensitivity  Check  Index  
RAPA    Rapid  Assessment  of Physical  Activity  
SAE   Serious  adverse  event  
SD   Standard  Deviation  
SOA     Schedule  of Activities  
TUG    Timed  Up and Go 
UENS    Utah  Early  Neuropathy  Scale  
  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  9 of 67 SYNOPSIS  
Title:   Topiramate  as a Disease  Modifying  Therapy  for Cryptogenic  Sensory  Peripheral  
Neuropathy  in Metabolic  Syndrome :  The “TopCSPN  Study”  
 
Short  Title:   The TopCSPN  Study  
 
Primary  Objective:   Determine  if oral topiramate  slows  progression  of CSPN  using  intraepidermal  
nerve  fiber density  (IENFD)  as a primary  measure  of axon  loss and the Norfolk  Quality  of Life –
Diabetic  Neuropathy  (NQOL -DN) as a measure  of neuropathy  related  quality  of Life. 
 
Secondary  Objective:   Determine  the patient  focused  clinical  relevance  of change  in IENFD  and 
other  CSPN  surrogate  measures  using  measures  of pain,  QOL,  balance  and mobility.    
 
Design  and Outcomes:   The TopCSPN  study  will consist  of screening  and baseline  visits,  safety  
and monitoring  visits  every  16 weeks , evaluation  visits  at 32 and 64 weeks , a 96-week  end-of-
treatment  visit, and a final safety  assessment  visit following  termination  of study  drug.  Distal  thigh  
IENFD  and the NQOL -DN will serve  as co-primary  outcome  measures.  
 
Interventions  and Duration:   The proposed  study  is a 96-week  double  blind  randomized  placebo -
controlled  trial of topiramate  at a target  dose  of 100 mg daily (50 mg twice  daily)  as a potentially  
disease  modifying  therapy  for cryptogenic  sensory  peripheral  neuropathy  (CSPN).  Randomized  
participants  will return  to the clinic  for follow  up visits  every  16 weeks .  Evaluation  visits  will occur  
at 0, 32, 64 and 96 week s.  Enrollment  will occur  over a 48-week  period.   Dropout is estimated  to 
be 4% at 32 weeks , 8% at 64 weeks , and 12% at 96 weeks .  
 
Sample  Size and Population:   After  a screening  period,  a total of 125 male  and female  participants  
from 18 to 80 years  of age, inclusive,  will be enrolled  into two treatment  arms  (topiramate  100 mg 
daily or matching  placebo).   Enrollment  will be stratified  by body  mass  index  (BMI).  
 
1. STUDY  OBJECTIVES  
1.1. Primary  Objectives  
The primary  objective  of this study  is to determ ine if oral topiramate  slows  neuropathy  progression  
and improves  patient  relevant  outcomes.  Change  in Intraepidermal  Nerve  Fiber  Density  (IENFD)  
and in the validated  Norfolk  Quality  of Life-Diabetic  Neuropathy  (NQOL -DN) scale  will serve  as 
co-primary  endpo ints. The study  will be considered  positive  if there  is significant  treatment  effect  
for both,  or efficacy  in one and noninferiority  in the other  (see the Go/No -Go section  for details  of 
the predefined  algorithm).   
 
 
The primary  objective  is to determine  if topiramate  alters  the natural  history  of progressive  decline  
in Intraepidermal  Nerve  Fiber  Density  (IENFD)  and improves  neuropathy  related  quality  of life. A 
positive  signal  for both primary  outcome  measures  (Intrae pidermal  Nerve  Fiber  Density  and 
Norfolk  Quality  of Life-Diabetic  Neuropathy)  would  support  additional  study.   
Lack  of improvement  in either  IENFD  or NQOL -DN would  indicate  a Phase  III trial of topiramate  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  10 of 67 as either  a disease  modifying  or symptomatic  agent  for Cryptogenic  Sensory  Peripheral  
Neuropathy  (CSPN)  was not warranted.   A predefined  detailed  Go-No Go algorithm  is provided  
in the statistical  methods  section.   If there  is treatment  efficacy  in one endpoint  and noninferiority  
in the other  the trial will be considered  possible.   
  
Pain,  falls and reduced  mobility  due to distal  sensory  nerve  injury  reduce  quality  of life (QOL)  in 
patients  with Cryptogenic  Sensory  Peripheral  Neuropathy  (CSPN).  The 47-item Norfolk  Quality  
of Life –Diabet ic Neuropathy  (NQOL -DN) Scale  is a validated  neuropathy  specific  patient  reported  
outcome  measure  developed  following  1,000  structured  patient  interviews.  The scale  includes  
small  fiber,  large  fiber,  autonomic,  symptoms,  and activities  of daily living  subs cores27.  The scale  
has been  translated  into 10 languages  including  Spanish40. The NQOL -DN captures  symptoms  
related  to diabetic  neuropathy,  which  are in turn very similar  to those  experienced  by CSPN  
patients.  The NQOL -DN is responsive  to change  and significantly  correlates  with other  clinical  
and confirmatory  measures  of neuropathy27 and has shown  utility  in both diabetic  and familial  
amyloid  polyneuropathy  related  to transthyretin  mutations41. The mean  total NQOL -DN among  
379 American  and European  patien ts with mild diabetic  neuropathy  was 27.3.   However,  many  
patients  with diabetes  who do not have  neuropathy  answered  affirmatively  to a number  of the 
general  QOL  questions.   Therefore,  the NQOL -DN score  for patients  with moderate  CSPN  are 
expected  to be much lower.   Inclusion  criteria  will require  a NQOL -DN score  of >9 in order  to 
ensure  some  degree  of baseline  neuropathy  related  disability.28 This cutoff  was selected  following  
discussions  with the scale’s  developer.  
 
Cryptogenic  Sensory  Peripheral  Neuropat hy (CSPN)  is clinically  characterized  by early  injury  to 
small  unmyelinated  axons,  resulting  in denervation  of the epidermis  (reflected  in reduced  
Intraepidermal  Nerve  Fiber  Density  (IENFD)  and positive  sensory  symptoms  including  pain.  
Measures  of small  fiber function  typically  decline  before  those  reflecting  large  fibers42. These  
features  make  IENFD  an appropriate  objective  measure  of change  in peripheral  nerve  integrity.  
IENFD  is more  sensitive  than quantitative  sensory  testing  or nerve  conduction  studies  (NCS)  in 
detection  of idiopathic  43 and diabetic  and prediabetic  neuropathy10,44. IENFD  is responsive  to 
treatment  and shows  at least  transient  improvement  with exercise  intervention  in patients  with 
neuropathy  associated  with both diabetes  and metabolic  syndrome10,11.   
1.2. Secondary  Objectives  
The secondary  aim is to evaluate  clinical  meaning  of change  in Intraepidermal  Nerve  Fiber  
Density  (IENFD),  and examine  the relative  contribution  of its change  to improvement  in clinically  
meaningful  outcomes.  
 
2. BACKGROUND   
2.1. Target  Population   
The target  population  is patients  with Cryptogenic  Sensory  Peripheral  Neuropathy  (CSPN),  also 
commonly  referred  to as idiopathic  neuropathy.   Between  1/3 and 1/2 of patients  with distal  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  11 of 67 symmetric  polyneuropathy  have  no identi fiable  cause  for neuropathy  on detailed  laboratory  
evaluation3,63.  As summarized  in sections  2.3 and 2.4 there  is an expanding  body  of data linking  
obesity  and its metabolic  consequences  to CSPN  risk.  Insulin  resistance  and glucose  intolerance  
are presen t in up to 50% of CSPN  patients2.  Metabolic  syndrome  (defined  as three  of the 
following:  prediabetes/diabetes,  central  obesity,  low HDL,  elevated  triglycerides,  and 
hypertension)  is observed  in >80%  of patients  with CSPN  with IGT, and over 50% of those  with 
normal  glucose  tolerance.  
2.2. Study  Timeline  
Once  enrollment  begins,  the study  will take approximately  four years  to complete.   A lead-in period  
of 32 weeks  will be followed  by the recruitment  phase.   Recruitment  is anticipated  to take 48 
weeks  from first subject  enrolled . A total of 125 subjects  will be randomized  into the study .  All 
subjects  will be followed  for 96 weeks .  The last subject  visit is anticipated  to occur  approximately  
144 weeks  after first subject  enrolled.  Data  cleaning  and analysis  will be completed  within  16 
weeks  following  study  closure.   
2.3. Rationale  
Peripheral  neuropathy  affects  >10%  of those  over 40 years  old 1, approximately  half of whom  
have  cryptogenic  sensory  peripheral  neuropathy  (CSPN),  resulting  in reduced  quality  of life (QOL)  
due to pain,  sensory  loss, imbalance,  and fall related  injuries.  CSPN  is a significant  cause  of 
patient  morbidity,  for which  there  exists  no disease  modifying  therapy.   Clinically  similar  to early 
diabetic  neuropathy,  it is characterized  by preferential  injury  to small  axons,  and frequently  results  
in prominent  sensory  loss and neuropathic  pain.   While  the precise  etiology  of CSPN  is unknown,  
and likely  multifactorial,  accumulating  evidence  indicates that obesity,  dyslipidemia,  and insulin  
resistance/prediabetes  (metabolic  syndrome)  are linked  to CSPN  risk2.  Patients  with CSPN  have  
an elevated  risk of metabolic  syndrome3,4 and patients  with prediabetes  have  an elevated  risk of 
CSPN5.  Obesity  and dyslipidemia  also significantly  increase  the risk of neuropathy  among  
diabetic  patients6.  Animal  models  support  the hypothesis  that obesity  and prediabetic  levels  of 
glucose  dysregulation  cause  neuropathy7-9.    
 
Our previous  studies  show  that exercise  improves  nerve  regenerative  capacity,  results  in 
increased  intraepidermal  nerve  fiber density  (IENFD)  and improves  pain among  patients  with 
CSPN  and prediabetes  10. Together,  these  findings  suggest  CSPN  is potentiall y reversible.    
However,  lifestyle  interventions  are clinically  limited  by noncompliance  and poor sustainability.  
While  randomized  clinical  trials  of strategies  to treat metabolic  syndrome  in CSPN  are lacking,  
the available  data suggest  aggressive  manageme nt of metabolic  syndrome  components  may be 
effective.  The NINDS  funded  Impaired  Glucose  Tolerance  Neuropathy  (IGTN)  study  
demonstrated  that one year of diet counseling  and exercise  based  on the protocol  used  in the 
Diabetes  Prevention  Program  (DPP)  resulte d in improved  IENFD  and reduced  pain among  
patients  with CSPN  and impaired  glucose  tolerance  (IGT)10.  A similar  study  in patients  with 
diabetic  neuropathy  found  consistent  results11.  The Steno -2 trial demonstrated  that aggressive  
management  of metabolic  syndrome  features  resulted  in a significantly  reduced  risk of autonomic  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  12 of 67 neuropathy  compared  to those  treated  conventionally12.  There  was no impact  on vibration  
sensation  assessed  using  a biothesiometer,  suggesting  particularly  robust  therapeutic  benefit  for 
small  diameter  axons  (the fiber population  for which  topiramate  has shown  promise).   Our 
preliminary  data indicate  aggressive  exercise  results  in enhanced  peripheral  nerve  regeneration  
capacity  in metabolic  syndrome  patients.   Cumulatively,  these  data support  the hypothesis  that 
metabolic  syndrome  is linked  to CSPN  risk, and that aggressive  management  may be an effective  
strategy  to enhance  nerve  regeneration  and improve  patient  symptoms.   However,  currently  
available  lifestyle  interventions  are very difficult to employ  in a clinical  setting  due to poor 
compliance  and attrition  from the necessary  behavioral  changes.  Development  of better  
pharmacologic  approaches  is a major  priority.   
2.4. Supporting  Data  
Topiramate  is a promising  therapeutic  approach  to CSPN.  Clinical  trials  of this anticonvulsant  
agent  in diabetic  neuropathy  suggest  improvement  in pain and QOL,  but also in measures  of 
peripheral  nerve  function  including  sensory  testing  and IENFD.13.  Topiramate  has multiple  
potentially  neuroprotective  effects,  including  sodium  channel  inhibition,  increased  insulin  
sensitivity,  and significant  weight  loss, which  is greatest  among  obese  patients  14,15.    It has been  
extensively  studied  for the treatment  of epilepsy  and migraine  and is generally  safe and well 
tolerated.   Several  studies  suggest  a potential  benefit  for neuropathic  pain associated  with 
diabetic  neuropathy.   The CAPSS -141 study  enrolled  323 patients  with painful  neuropathy  and 
found  a significant  improvement  in pain severity,  with a 50% response  rate (>30%  pain reduction)  
over 12 weeks  compared  to 34% for placebo  (p<0.004)16. A 26-week  open  label  extension  study  
involving  225 participants  demonstrated  a durable  treatment  benefit17,18.  Three  studies  with 
similar  design19,20, failed  to demonstrate  pain efficacy,  but were  limited  by a high placebo  response  
rate and use of a less specific  visual  analog  pain outcome  measure  21.  Small  studies  suggest  
topiramate  therapy  not only results  in improved  pain,  but also improves  QOL  and preferentially  
impacts  meas ures of small  fiber function,  including  an increase  in IENFD22,23. Data  from animal  
models  of diabetes  also support  its potential  therapeutic  efficacy24,25.  We hypothesize  that 
topiramate  will significantly  slow the natural  history  of IENFD  decline  and will improve  neuropathy  
specific  QOL  in patients  with CSPN.  
 
Topiramate  has multiple  potential  therapeutic  mechanisms  relevant  to neuropathy.   It is 
associated  with significant  weight  loss that may result  in improved  insulin  resistance  and reduction  
of overall  metabolic  risk for neuropathy.   There  are currently  5 drugs  available  in the United  States  
for long-term weight  loss: orlistat,  lorcaserin,  phentermine -topiramate  (Qysmia),  naltrexone -
buproprion  and liraglutide.   Mean  weight  loss varies  from 4-9%, with phentermine -topiramate  
generally  demonstrating  the highest  mean  weight  loss (8.6-9.3%),  with 70% of treated  patients  
experiencing  >10%  weight  loss26. Topiramate  monotherapy  is associated  with weight  loss on par 
with other  approved  weight  loss medicati ons and greater  than that observed  in the IGTN  Study  
and other  studies  of exercise  and diet for neuropathy.   Obese  diabetic  patients  treated  with 
topiramate  alone  lost 6.6%  of body  weight  over 11 months,  most  of which  was lost in the first 5 
(5.5%)  27,28. A recent  meta -analysis  of topiramate  trials  found  an average  weight  loss of 5.34 kg 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  13 of 67 among  3320  individuals  (6.58  kg for those  treated  > 28 weeks)21.  The CAPSS -141 study  of 
topiramate  for diabetic  neuropathy  demonstrated  a 2.6 kg weight  loss over 12 weeks22, and a 5.2 
kg weight  loss over 38 weeks  in the open  label  extension23.  Weight  loss was greatest  in obese  
individuals.   Among  38 epilepsy  patients  treated  with topiramate,  there  was a mean  weight  loss 
of 7.3%  at one year.   Among  those  with a BMI of >30 kg/m2 the one-year weight  loss was 11%.  
Weight  loss at 3 months  was associated  with reduced  caloric  intake.   Afterwards,  caloric  intake  
returned  to normal  but weight  loss continued,  and ultimate  weight  loss was correlated  with loss of 
body  fat mass.   These  data suggest  weight  loss is due to additional  mechanisms  other  than 
appetite  suppression29.  Topiramate  leads  to weight  loss and reduced  adiposity  in rodent  models  
and humans  via decreased  food intake  and energy  expenditure  that is mediated  by improved  
insulin and leptin  signaling  at the hypothalamic  level30. Multiple  studies  demonstrate  that 
topiramate  improves  insulin  sensitivity  independent  of its weight  loss effects30-32. Data  from a high 
fat fed mouse  model  indicate  improved  insulin  sensitivity  is driven by uptake  in adipose  tissue,  
and blocked  by intravenous  tolbutamide,  suggesting  central  nervous  system  uptake  is necessary  
for this metabolic  benefit19. In a high fat fed rat model,  topiramate’s  insulin  sensitizing  effects  were  
in part mediated  at the hepatic  level by modulation  of insulin  receptor  isoforms,  increased  
adiponectin  production  and receptor  expression,  and lower  TNF   levels20. As with neuropathy,  
animal  models  support  its potential  efficacy  as a weight  loss therapy,  and also demonstrated  
improvement  in insulin  sensitivity  that may be independent  of weight  loss effects30-33.   
 
Beyond  improvement  in weight  and obesity -related  metabolic  consequences,  topiramate  inhibits  
voltage -gated  sodium  and calcium  channels22,34.  There  is evolving  data linking  changes  in 
voltage -gated  sodium  channel  function  to CSPN,  including  a recent  report  of a high prevalence  
of SCN9A  sequence  variants  in patients  with otherwise  idiopathic  isolated  small  fiber 
involvement14,17. In these  patients,  with prominent  neuropathic  pain,  sodium  channel  mutation  
leads  to increased  sensory  axon  irritability,  suggesting  a pharmacological  role for sodium  channel  
inhibition.  It is likely  that analogous  acquired  altered  sodium  channel  function  is linked  to other  
forms  of neurop athy,  including  diabetic  and chemotherapy  induced  neuropathies35-37. Alterations  
in cellular  excitability  may both increase  pain and lead to axon  loss and progressive  neuropathy38. 
Development  of a well-tolerated  small  molecule  approach  to blockade  of voltage gated  sodium  
channels  is a priority.   Topiramate  has been  shown  to reduce  peripheral  nerve  excitability,  likely  
via inhibition  of voltage  gated  sodium  channels34,39.  While  topiramate  has multiple  potential  
mechanisms  of action  (weight  loss, improved  insulin  sensitivity,  sodium  channel  modulation),  the 
fact that each  would  be expected  to have  potential  benefit  in CSPN  supports  its further  evaluation  
as a disease  modifying  therapy.  
 
While  topiramate  doses  used  in diabetic  neuropathy  trials  have  varied  from 100-400 mg daily,  
data from two small  trials  suggest  100 mg/day  is associated  with improvement  in both IENFD  and 
neuropathy  specific  QOL  assessed  using  the Norfolk  Quality  of Life –Diabetic  Neuropathy  (NQOL -
DN) scale.24,25.  Doses  above  100mg  daily are more  likely  to be associated  with neuro -cognitive  
side effects.   A Cochrane  review  of the use of topiramate  for headache  suggests  there  is no 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  14 of 67 additional  benefit  to doses  over 100 mg daily.   In light of the greater  risk of side effects  at doses  
over 100 mg daily,  these  data support  selection  of the 100 mg/day  target  dose.  
 
3. STUDY  DESIGN  
This is a 96-week  double  blind  randomized  placebo -controlled  trial of topiramate  at a target  dose  
of 100 mg daily (50 mg twice  daily)  as a potentially  disease  modifying  therap y for CSPN.   After  a 
screening  period,  a total of 125 male  and female  subjects  from 18 to 80 years  of age, inclusive,  
will be enrolled  into two treatment  arms  (topiramate  100 mg daily or matching  placebo).  
Randomized  subjects  will return  to the clinic  for follow  up visits  on a regular  basis.   Enrollment  will 
occur  over a 48-week  period.   All subje cts will be followed  for 96 weeks . 
 
The study  will consist  of screening  and baseline  visits,  safety  and monitoring  visits  every  16 
weeks , evaluation  visits  at 32, 64, and 96 weeks , and a final safety  assessment  visit following  
termination  of study  drug. The figure  below  displays  the anticipated  recruitment  schedule  and 
number  of evaluable  subjects  at each  visit, accounting  for 12% dropout  over 96 weeks . A 
Schedule  of Assessments  associated  with each  visit is provided  at the end of the protocol  in 
Appendix  A.  
 
 
 
Participants  will be seen  for a screening  visit, of which  up to 30 days  will be allotted  to complete  
the screening  assessments.  After  informed  consent  is obtained,  the investigator  will review  
inclusion/exclusion  criteria  with the participant,  obtain  a medical,  family,  and neurological  history  
and perform  a general  medica l and detailed  neuromuscular  physical  examination  including  vital 
signs.  Concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies,  will be 
recorded.   
 

 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  15 of 67 After  meeting  all entry  criteria,  participants  who continue  to meet  all inclusion/exclusion  criteria  
after screening  will present  to the clinic  for the baseline  visit.  The baseline  visit will be performed  
within  30 days  of the screening  visit.  However , the investigator  will review,  date and initial  the 
screening  laboratory  assess ments  to confirm  participant  eligibility  for study  participation  prior to 
the baseline  visit procedures.  Therefore,  adequate  time must  be provided  for the laboratory  
results  to be received  from the central  laboratory.  The investigator  or designee  will again review  
the study  inclusion/exclusion  criteria  and participant  medical  history,  confirming  that the 
participant  meets  criteria  for study  participation  before  randomization.   
 
Participants  will be seen  for safety  and follow -up visits  at 16, 48 and 80 weeks  following  the 
baseline  visit. Participants  will be seen  for evaluation  visits  at 32, 64 and 96 weeks . All tests  listed  
for the quarterly  monitoring  visits  will be performed  at each  of these  visits  in addition  to NCS,  
distal  thigh  skin biopsy  for IENFD,  functional  and mobility  testing,  laboratory  monitoring  for 
metabolic  status  (fasting  insulin  and glucose,  fasting  lipid panel,  hemoglobin  A1c).  The final study  
treatment  visit will occur  96 weeks  following  baseline.   All assessments  performed  at the 
evaluati on visits  will take place.   The investigator  will perform  a complete  physical  examination.   
All study  drug and study  drug packages  will be collected  from the participant  at this visit and a 
final assessment  of study  drug compliance  will be calculated.  A final safety  visit will occur  by 
telephone,  or in person  at the discretion  of the site PI, 4 weeks  (± 7 days)  following  the last dose  
of study  drug.  
 
4. SELECTION  AND  ENROLLMENT  OF SUBJECTS  
4.1. Inclusion  Criteria  
1. Age 18-80  
2. Diagnosis  of confirmed  cryptogenic  symptomatic  distal  symmetric  peripheral  
polyneuropathy  based  on the Toronto  consensus  criteria  for probable  neuropathy  (the 
presence  of unequivocal  signs  and symptoms  of neuropathy )45. 
3. Evidence  of symptomatic  neuropathy  based  on a screening  visit NQOL -DN score  of >9  
4. Metabolic  syndrome  based  on modified  ATPIII  criteria,  with a BMI ≥ 25 kg/m2 46 . Specific  
criteria  require  3 of the following  6 to be present  at the screening  visit. 
o Waist  circumference  >102  cm for men,  >88 cm for women  
o Serum  triglycerides  of > 150 mg/dl  
o HDL < 40 mg/dl  for men,  < 50 mg/dl  for women   
o Those  with either  a normal  HDL or TRG  who are taking  a lipid lower ing medication  
for this purpose.  
o Blood  pressure   130/85  mm Hg or use of anti-hypertension  drug 
o Prediabetes  based  on American  Diabetes  Association  (ADA)  criteria  at screening  
based  on any one or more  of the following :  fasting  plasma  glucose  - 100 mg/dL  to 
125 mg/dL  (5.6 mmol/L  to 6.9 mmol/L) ,  
2-hour glucose  tolerance  test - 140 mg/dL  to 199 mg/dL  (7.8 mmol/L  to 11.0 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  16 of 67 mmol/L) , or hemoglobin  A1c between  5.7%  and 6.4% . 
5. No current  or prior history  of therapy  with topiramate.    
6. If female  of child-bearing  potential  (i.e., not surgically  sterile  or post-menopausal  defined  
as age > 51 years  without  menses  for ≥ 2 years),  negative  serum  pregnancy  test at 
screening  and negative  urine  pregnancy  test at baseline  visit. 
7. Women  of child-bearing  potential  or men with sexual  partners  of childbearing  potential  be 
willing  to use an acceptable  method of birth control  for the duration  of the study  and for 12 
weeks  following  completion  of study  drug therapy.   Acceptable  methods  of birth control  
include  abstinence,  oral contraceptives,  the contraceptive  patch,  intra-uterine  device,  the 
contraceptive  ring, and or barrier  contraception  such  as condoms  with spermicide.   
4.2. Exclusion  Criteria  
1. CSS-PI clinical  determination  of an alternative  cause  for peripheral  neuropathy  (including  
but not limited  to rheumatological  disorders , Hepatitis  B or C, Breast  Cancer  treated  with 
neurotoxic  chemotherapy  within  the past 15 years) . All potential  subjects  will have  
screening  neuropathy  labs including  assessment  for diabetes  (Hemoglobin  A1c, oral 
glucose  tolerance  test),  vitamin  B12 level,  and immunofixation47. 
2. Diagnosis  of diabetes  by history,  or screening  laboratory  results  including:   HgA1c  ≥ 6.5% , 
fasting  plasma  glucose  ≥ 126 mg/dL  (7.0 mmol/L) , or 2-hour oral glucose  tolerance  ≥ 200 
mg/dL  (11.1  mmol/L) .  Borderline  screening  labs can be repeated  within  two weeks  with 
PPI approval.  
3. History  of recurrent  nephrolithiasis , a single  episode  of nephrolithiasis  within  one year prior 
to screening,  or use of ongoing  preventative  treatment.   
4. Family  history  of a hereditary  neuropathy  in a first-degree  relative.   
5. Severe  neuropathy:  Utah  Early  Neuropathy  Score  > 24 at screening  
6. Active  foot ulceration  or a history  of a nontraumatic  foot amputation.  
7. ECG  with QTc more  than 450 ms in men,  or 470 ms in women.   
8. Current  or planned  therapeutic  anticoagulation  including  coumadin  or oral factor  X or 
thrombin  inhibitor  therapy  (anti-platelet  agents  are permissible).   
9. Chronic  corticosteroid  use excluding  topical  or inhaled  treatment.   
10. Use of a carbonic  anhydrase  inhibi tor (such  as acetazolamide)  due to risk of 
nephrolithiasis.  
11. Planned  bariatric  surgery  
12. Use of other  weight  loss medications.  
13. Use of scheduled  opiates,  or as needed  opiate  medications  more  than three  times  weekly.   
14. Use of topical  capsaicin  products  within  16 weeks  of screening  or at any time on study.  
15. Medication  change  for neuropathy  symptoms  during  the 8 weeks  prior to screening;  or 
anticipated  change  for the duration  of study  participation.  
16. Current  use of an intrathecal  pain pump  or spinal  cord stimulator.   
17. Screening  laboratory  creatinine  ≥ 2.0 mg/dl.  
18. Severe  edema,  dermatologic  or lower  extremity  condition  that would  increase  risk of skin 
biopsy.   
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  17 of 67 19. Major  depression,  bipolar  affective  disorder,  or other  mental  health  disorders  that are 
sufficiently  severe  to increase  adverse  event  risk or impact  neuropathy  assessment  in the 
opinion  of the responsible  site principal  investigator.  
20. Current suicidal ideation within one year prior to the baseline visit as evidenced by 
answering “yes” to Questions 4 or 5 on the suici dal ideation portion of the Columbia -
Suicide  Severity  Rating  Scale  (C-SSRS). 
21. Ataxia  sufficiently  severe  to represent  an unacceptable  fall risk in the opinion  of the site 
principal  investigator.  
22. A serious  medical  condition  expected  to dramatically  shorten  life span  or prevent  
participation.   
23. Any clinically  significant  condition  or illness,  which,  in the opinion  of the CSS-PI, would  
pose  a risk to the subject  or might  confound  the study  including  metabolic  acidosis,  bone  
marrow  suppression,  blood  dyscrasias,  bleeding  disorder,  or closed  angle  glaucoma.  
24. History  of alcohol  or drug abuse  within  the past two years , or existing  neuropathy  related  
to past drug or alcohol  abuse . 
25. History  of malignancy  within five years  prior to study  enrollment,  except  for adequately  
treated  basal  cell or squamous  cell skin cancer  or in situ cervical  cancer.  
26. A history  of epilepsy.  
27. An inability  to understand  or cooperate  with the procedures  of the study.  
28. Pregnant,  or intending  to become  pregnant,  or breastfeeding.  
 
ADA  Diagnostic  Criteria  for Diabetes  and Prediabetes  
Diagnosis  Fasting  Plasma  Glucose  2-Hour  Oral Glucose  
Tolerance  Test 
 Hemoglobin  
A1C 
Normal  < 100 mg/dL  (5.6 mmol/L)  
 < 140 mg/dL  (7.8 mmol/L)  < 5.7%  
Prediabetes  100 mg/dL  to 125 mg/dL  
(5.6 mmol/L  to 6.9 mmol/L)  
 140 mg/dL  to 199 mg/dL  (7.8 
mmol/L  to 11.0 mmol/L)  5.7%  to 6.4%  
Diabetes  
(excluded)  ≥ 126 mg/dL  (7.0 mmol/L)  ≥ 200 mg/dL  (11.1  mmol/L)  ≥ 6.5%  
 
4.3. Subject  Withdrawal  Criteria  
A subject  may discontinue  study  drug or withdraw  from study  participation  at any time without  
bias for any of the following  reasons:  
 
Administrative  
1. Withdrawal  of consent  by subject  
2. Request  of Study  Sponsor  or Principal  Investigator   
3. Request  of primary  care physician  
4. Pregnancy  (must  stop study  drug) 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  18 of 67 5. Subject  deemed  lost to follow  up/failure  to return  
6. Early  termination  of study  
7. Other   
 
Adverse  Event  
1. Worsening  of the disease  under  study  
2. Worsening  of pre-existing  disease  (other  than disease  under  study)  
3. Intercurrent  illness  
4. Death  
5. Major/clinically  significant  alteration  in laboratory  values  after beginning  study  drug 
6. Prolonged  QTc  
7. Active  suicidal  Ideation  based  on the C-SSRS  
8. Other  adverse  event  
 
4.4. Study  Enrollment  Procedures  
Subjects  will be recruited  from 14 NeuroNEXT  sites and 1 non-NN site in the United  States.   
Investigators  will be responsible  for obtaining  written  consent  from each  potential  subject  after 
adequate  explanation  of the purpose,  study  procedures,  and any risks associated  with the study.   
 
Treatment  for each  subject  will be assigned  by a randomized  code.  A block  randomization  
scheme  will be used  to ensure  approximately  even  distribution  of subjects  in treatment  groups  for 
each  BMI strata . 
4.4.1.  Subject  Recruitment  and Retention  
Subjects  will be recruited  from clinics  at participating  NeuroNEXT  Network  sites.  Postings  will be 
placed  on selected  website (s). Flyers  about  the study  will be sent to community  neurologists  at 
NeuroNEXT  clinical  sites.  Webinars  will be conducted  for subject  recruitment  as needed.   
Interested  subjects  will be contacted  by the investigators  or their staff and invited  to participate.  
These  recruitment  strategies  will include  a mechanism  by which  the patients  can provide  their 
contact  information.  We will use the NeuroNEXT  Recruitment  and Retention  Committee  to identify  
recruitment  strategies.   
4.4.2.  Screening  Logs  
All clinical  sites will maintain  screening  logs documenting  demographic  information  including  age, 
gender,  race and ethnicity,  reasons  for ineligibility  at the screening  visit, and reasons  for non-
participatio n if eligible.   
 
Screening  logs to document  demographic  information  and reasons  for ineligibility  and non-
participation  will be stored  centrally  at the NeuroNEXT  Data  Coordination  Center.  Information  
about  screening  failures  and successes  will be compiled  and reviewed  on a periodic  basis  so that 
feedback  can be provided  to sites.  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  19 of 67  
Screening  log data will be provided  to the study  team,  de-identified  and analyzed  to determine  
the most  successful  routes  for information  dissemination  and recruitment  strategies  for ongoing  
recruitment  in this study  and for future  studies.  The study  team  will work  to identify  any common  
reasons  for screen  failure  that might  be identified  to consider  amendments  to the study  to adjust  
inclusion/exclusion  criteria  if a large  number  of patients  are screen  failing  for specific  reasons  that 
would  not ultimately  affect  the study  results  if allowed.  Likewise , reasons  for non-enrollment  will 
be tracked  centrally.  If there  are recurring  themes  adjustments  will be attempted  to target  this 
problem,  as long as the adjustments  do not affect  the study  conduct  or data quality.  
4.4.3.  Informed  Consent  
Written  informed  consent  will be obtained  from each  study  participant  before  any study -specific  
procedures  or assessments  are done  and after the aims,  method s, anticipated  benefits,  and 
potential  hazards  are explained.  The participant’s  willingness  to participate  in the study  will be 
documented  in writing  in a consent  form approved  by the NeuroNEXT  Central  Institutional  Review  
Board  (CIRB),  which  will be signe d by the participant  with the date of that signature  indicated.  
The investigator  will keep  the original  consent  forms  and a copy  will be given  to the participant.  It 
will also be explained  to the participant  that they are free to refuse  entry  into the study and free to 
withdraw  from the study  at any time without  prejudice  to future  treatment.  Written  and/or  oral 
information  about  the study  in a language  understandable  by the participant  will be given  to all 
participants.  
 
Informed  consent  will be obtained  by licensed  physician  investigators  only,  who are trained  on 
the study  and delegated  appropriately  as being  authorized  to obtain  consent.  The site PI will 
typically  be involved  in explaining  the study  and will play a role during  the consent  process  and 
answ ering  any questions  in conjunction  with the coordinator,  as well as overseeing  that the 
process  is carried  out correctly.   
 
Optional  DNA  and tissue  banking  is planned  for future  research.  Participants  will consent  to their 
preference  for banking  DNA  and tissue  separately.     
4.4.4.  Assent  
Children  (age less than 18) will not be allowed  to participate  in this study.   
4.4.5.  Randomization/Treatment  Assignment  
Randomization  to study  treatment  (either  topiramate  or matching  over- encapsulated  placebo)  will 
occur  using  an interactive  web response  system  (IWRS).   Online  randomization  will follow  
confirmation  of eligibility  and completion  of all required  baseline  procedures.  Randomization  
codes  will be constructed  using  random  permuted  blocks  to assure  balanced  randomization  over 
time with stratification  by BMI. BMI of 30.0 will serve  as stratification  cutoffs  reflecting  anticipated  
median  values.    
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  20 of 67 Following  randomization,  subjects  will be given  a supply  of study  drug with instructions  to take 
the study  drug twice  daily using  a 2-week  dose  escalation  schedule.   Subjects  will titrate  to two 
25mg  tablets  twice  daily,  or the maximally  tolerated  dose.  
 
5. STUDY  INTERVENTIONS/  STUDY  DRUG   
5.1. Study  Drug  and Dose  Selection  
The intervention  under  study  is oral topiramate,  100mg  daily taken  in two divided  doses  of 50mg.   
Matching  placebo  will be identical  to topiramate  in color,  shape,  and packaging.    
5.2. Dose  selection  
Previous  studies  have  evaluated  topiramate  as a potential  therapy  for pain associated  with 
diabetic  neuropathy  with mixed  results.   The dose  in these  trials  varied  from 100-400 mg 
daily22,23,64.  The objective  of this study  is to evaluate  the potential  efficacy  of topiramate  as a 
disease  modifying  therapy  for CSPN  associated  with metabolic  syndrome.  Randomized  trials  in 
diabetic  neuropathy  have  demonstrated  that a dose  of 100 mg/day  is sufficient  to improve  both 
neuropathy  associated  QOL  (as measured  by NQOL -DN) and thigh  IENFD  24,25, while  side effects 
of decreased  concentration  or fatigue  were  more  common  at higher  doses.   Similarly,  a Cochrane  
review  reported  no additional  benefit  to doses  over 100 mg daily in topiramate  trials  for 
headache65.  In light of the greater  risk of side effects  at doses  over 100 mg daily,  these  data 
support  selection  of the 100 mg/day  target  dose.  
5.3. Formulation  and Packaging  
Study  drug,  or matching  placebo,  will be provided  in labeled  packages  with sufficient  product  for 
study  subjects  to take four capsules  daily for 16 weeks, with sufficient  overage  in each  package  
to allow  for anticipated  variation  in visit scheduling.   Four 132-count  bottles  will be provided , 
permitting  for 14 days  of overage .  Each  study  test article  packet  will be labeled  with the following  
information : 
 
 Name  of Sponsor  
 Name  and address  of study  drug distribution  center  
 Study  number  and IND number  
 Unique  drug package  number  
 Drug  treatment  label  (each  kit will list either  25 mg topiramate  or placebo)  
 Route  of administration  
 Quantity  of dose  unit 
 Directions  for use 
 Storage  conditions  
 Space  for investigator  name,  telephone,  dispensing  date and subject  number  
 Space  for study  subject  identifier  
 Label  statement  “Caution:   New Drug -Limited  by federal  law to investigational  use” 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  21 of 67  Label  statement  “Cau tion:  Keep  out of reach  of children”  
5.3.1.  Supplies  and Dispensation  
Study  drug supplies  will be received  by the site investigator  or other  authorized  study  personnel  
at the study  site, managed  and stored  safely  and properly,  and kept in a secured  location  with 
restricted  access.   Study  staff with responsibility  for drug management  will keep  accurate  and 
complete  records  of study  drug received  by the site, dispensed  to study  subject,  and used  and 
returned  by study  subject.    
 
Study  drug will be dispensed  by appropriately  qualified  staff as designated  by the investigator’s  
delegation  of authority  log.  Subjects  will self-administer  the study  drug at home  following  the 
instructions  provided  to the subject  at the study  visit. The study  site investigator  will retain  returned  
study  drug,  or study  drug supplies  not dispensed  to subjects,  until the sponsor  provides  written  
instructions  for disposition.   
 
The study  case  report  forms  and source  documents  will include  prompts  to record  study  subject  
eligibility  to receive  study  drug,  study  drug dispensed,  dosing  start date,  dosing  end date,  missing  
doses,  and study  drug returned.     
5.3.2.  Titration  Schedule  and Dose Adjustments  
 
 Subjects  randomized  to the topiramate  arm will start 25mg  topiramate  once  daily in the evening.  
On day 4 following  randomization  a morning  dose  of 25 mg will be added.  On day 8 following  
randomization  an addition  25 mg tablet  will be added  in the evening,  and on day 12 a second  
morning  dose  will be added  so that the subject  will be taking  a total of 50mg  twice  daily.   Subjects  
who experience  an adverse  event  during  the dose  titration  may continue  at the highest  tolerated  
dose  for one week  prior to an additional  attempt  to increase  to the targeted  dose.   Those  who are 
tolerant  of a lower  dose  but intolerant  of the target  dose  will continue  on the highest  tolerated  
dose.   Results  will be analyzed  in an intent  to treat fashion.   If a subject  develops  a treatment  
related  adverse  event,  the dose  may be lowered  at the discretion  of the site PI in order  to establish  
a lower  maximally  tolerated  dose.   Those  who have  an adverse  event  and are unable  to continue  
medication  will undergo  a termination  visit.    
 
In accordance  with local regulatory  requirements,  the investigator,  designated  site staff,  or head  
of the medical  institution  (where  applicable)  must  document  the amount  of investigational  product  
dispensed  and/or  administered  to study  subjects,  the amount  received  from the central  pharmacy,  
and the amount  destroyed  upon  completion  of the study.  An investigator  is responsible  for 
ensuring  product  accountability  records  are maintained  throughout  the course  of the study.  The 
inventory  will include  details  of topiramate  received  and dispensed  to subjects,  batch,  and ID 
numbers.  All unused  capsules  must  be kept until reconciliation  of delivery  records  with 
accountability  logs by the monitor.  After  the monitor  has performed  accountability,  the site will be 
instru cted by the DCC or designee  to either  destroy  the remaining  study  drug or return  it to the 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  22 of 67 Central  Pharmacy  or manufacturer.  An accounting  must  be made  of any drug deliberately  or 
accidentally  destroyed.  Discrepancies  between  the amount  of topiramate  recei ved and dispensed  
drug must  be reconciled.  
5.4. Concomitant  Interventions  
The following  are permissible  as concomitant  interventions  for neuropathic  pain related  to CSPN  
if stable  for 8 weeks  prior to screening :  
• Gabapentin  
• Pregabalin  
• Tricyclic  antidepressants  
• Duloxetine  
• Venlafaxine  
• Tramadol  (200mg  daily or less) 
• Topical  lidocaine  
• Non-steroidal  anti-inflammatory  drugs  
 
The intent  of the protocol  is to keep  allowable  neuropathic  pain agents  and dosing  unchanged  
for the duration  of the study  (8 weeks  prior to screening  through  week  96).   
 
Marijuana,  cannabinoids,  and alpha lipoic  acid (ALA)  will be specified  as neuropathic  pain 
agent s on the concomitant  medication  form. These products  will not require  dosing  stability , but 
will be tracked  to evaluate  any potential  impact  on outcomes.  
 
If in the opinion  of the site investigator,  changes  in the permissible  neuropathic  pain agents  are 
required  for the safety  and/or  well-being  of the participant  between  baseline  and week  96/ET,  
the change  will be captured  in EDC and reported  to the PPI.  These  participants  will not be 
required  to discontinue  study  medication  or exit the study.   
 
5.4.1.  Prohibited  Medications/Interventions  
The following  medications/interventions  are exclusionary:   
• Therapeutic  anticoagulations  including  coumadin  or oral factor  X or thrombin  inhibitor  
therapy  
• Topical  capsaicin  
• Oral prednisone  
• Carbonic  anhydrase  inhibitor  (such  as acetazolamide)  
• Weight  loss medications  
• Neuropathic  pain agents  beyond  first line agents   
• Scheduled  opiates,  or as needed  opiate  medications  more  than three  times  weekly  
• Intrathecal  pain pump  or spinal  cord stimulator  
• Current  or prior history  of topiramate  therapy  
 
 
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  23 of 67 5.5. Subject  Compliance  
At each  study  visit, the site Investigator  and/or  Study  Coordinator  will assess  the subject’s  
compliance  with the study  requirements.  This will include  checks  for protocol  compliance,  
including  use of study  drug in order  to assess  the reliability  of subject -generated  data.  Subjects  
who fail to comply  with study  requirements  may be withdrawn  from the study.  
 
A  serum  topiramate  level will be measured  at baseline  and week s 32, 64, and 96 or ET to assess  
for compliance  or potential  crossover  (e.g. a participant  randomized  to placebo  taking  off study  
prescription  topiramate).   
 
Participants  will be aske d to hold their morning  dose  of study  medication  until after the blood  draw  
at weeks  32, 64, 96/ET.   The date and time of last dose  of study  drug will be recorded.    If the 
participant  does  not hold the prior dose,  the topiramate  level should  still be obtained.   These  data 
will not be shared  with the study  team  until after the study  has closed.  
 
 
6. STUDY  PROCEDURES  
6.1. Schedule  of Assessments  
Recruitment  will take place  over 48 weeks . The study  will consist  of screening  and baseline  visits,  
safety  and monitoring  visits  every  16 weeks , evaluation  visits  at 32, 64, and 96 weeks , and a final 
safety  assessment  visit or telephone  assessment  following  termination  of study  drug. A Schedule  
of Assessments  is provided  in Appendix  A.  
 
6.2. Visit  01 Screening  (Day  -30 to 0) 
Up to 30 days  will be allotted  to complete  the screening  assessments.  Prior  to any involvement  in 
study  related  activities,  the participant  must  sign and date a central  Institutional  Review  Board  
(IRB)  approved  written  informed  consent  form (ICF).   A copy  of the signed  and dated  ICF must  
be given  to the participant.  Screening  visit procedures  may be performed  over two consecutive  
days  if scheduling  constraints  prohibit  the completion  of all study  procedures  in a single  day. If 
screening  procedures  are completed  over two days,  the baseline  visit will occur  within  30 days  of 
the last screening  procedure  completion.    
 
The following  procedures  will be performed  at the screening  visit (this visit may take approximately  
3 hours):  
• Obtain  written  informed  consent  from participant.   
• Review  inclusion/exclusion  criteria.   
• Obtain  a medical,  family,  and neurological  history  to assess  for possible  exclusionary  
conditions.  Medical  histories  should  include  baseline  symptoms,  ongoing  illnesses,  other  
chronic  conditions,  surgical  history,  review  of currently  used  medications,  as well as any 
other  important  information  that may affect  the conduct  of the study.  See section  7.1.3.  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  24 of 67 • Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Administer  the Norfolk  Quality  of Life-Diabetic  Neuropathy  scale  (NQOL -DN). See section  
7.1.19 . 
• Perform  a general  medical  and detailed  neuromuscular  physical  examination.  See section  
7.1.5 . 
• Perform  vital sign measurements:  blood  pressure  (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6 .  
• Record  weight  (kg), height  (cm) and Body  Mass  Index  (BMI).  
• Record  waist circumference  (cm).  See section  7.1.7 . 
• Perform  a resting  12-Lead  ECG. See section  7.1.8 . 
• Collect  blood  samples  for CBC,  fasting  basic  metabolic  panel , fasting  insulin,  fasting  lipid 
panel,  two-hour OGTT,  HgbA1C,  Vitamin  B12, and serum  immunofixation  and serum  
pregnancy  test (pregnancy  test for women  of child-bearing  potential  only).  See section  
7.1.1 2. 
• Administer  the Utah  Early  Neuropathy  Scale  (UENS).  See section  7.1.10 . 
• Perform  clinical  assessment  for suicidal  ideation  with the Columbia -Suicide  Severity  
Rating  Scale  (C-SSRS ). See section  7.1.1 5. 
 
All clinical  and laboratory  evaluations,  procedures  related  to inclusion/exclusion  criteria,  or 
assessments  performed  during  treatment  will be reviewed,  initialed  and dated  by the Principal  
Investigator  or the individual  specifically  designated  by the investigator  on the delegation  of 
responsibility  (DOR)  log.   
 
6.3. Re-screening  
In the event  a participant  is originally  found  to be ineligible  at the screening  visit, but the 
investigator  believes  they may subs equently  be eligible  based  on changes  to the participant’s  
circumstances  or the study  protocol,  the participant  may return  for another  screening  visit (re-
screening  visit).  If the original  screening  visit was conducted  greater  than 90 days  before  the re-
screening  visit, the re-screening  visit will be treated  the same  as the original  screening  visit (see 
section  6.2).  
 
• If the original  screening  visit was conducted  within  90 days  prior to the re-screening  visit, 
the following  data may be re-used  from the original  screening  visit: 
o Serum  immunofixation  
o Two-hour OGTT   
o Vitamin  B12 results  
o Resting  12-Lead  ECG  
• If the original  screening  visit was conducted  within  30 days  prior to the re-screening  visit, 
the following  may be re-used  from the original  screening  visit: 
o General  medical  and detailed  neuromuscular  physical  examination  results .  
o Vital sign measurements  including  blood  pressure  (systolic  and diastolic),  heart  
rate (beats/minute),  and body  temperature  (°C).  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  25 of 67 o Weight  (kg) and height  (cm) measurements,  and the calculated  Body  Mass  Index  
(BMI).  
o Waist circumference  (cm) measurement .  
o Blood sample  results  for CBC,  fasting  basic  metabolic  panel , fasting  insulin,  fasting  
lipid panel,  two-hour OGTT,  HgbA1C,  Vitamin  B12, and serum  immunofixation  and 
serum  pregnancy  test (pregnancy  test for women  of child-bearing  potential  only).   
o Utah  Early  Neuropathy  Scale  (UENS)  results .  
o Columbia -Suicide  Severity  Rating  Scale  (C-SSRS ) results . 
 
• The following  procedures  must  be repeated  regardless  of timeframe  between  the original  
screening  visit and re-screening  visit: 
o Review  inclusion/exclusion  criteria.   
o Detailed  medical,  family,  and neurological  history  to assess  for possible  
exclusionary  conditions.   
o Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  
therapies.   
o Informed  Consent  
• If a participant  being  rescreened  had NCS  performed  as part of a prior screening  visit, 
these  data may be used  for baseline  data (assuming  the participant  proceeds  to 
randomization)  if the baseline  visit occurs  within  90 days  of the original  NCS  performance  
date. 
All clinical  and laboratory  evaluations,  procedures  related  to inclusion/exclusion  criteria,  or 
assessments  performed  during  treatment  will be reviewed,  initialed  and dated  by the Principal  
Investigator  or the individual  specifically  designated  by the investigator  on the delegation  of 
responsibility  (DOR)  log.   
 
6.4. Visit  02 Baseline  (Day  0) 
Participants  who continue  to meet  all inclusion/exclusion  criteria  after screening  will present  to 
the clinic  for the baseline  visit. The baseline  visit will be performed  within  30 days  of the screening  
visit. However,  the investigator  will review,  date and initial  the screening  laboratory  assessments  
to confirm  participant  eligibility  for study  participation  prior to the baseline  visit procedures.  
Therefore,  adequate  time must  be provided  for the laboratory  results  to be received  from the 
central  laboratory.  The investigator  or designee  will again  review  the study  inclusion/exclusion  
criteria  and participant  medical  history,  confirming  that the participant  meets  criteria  for study  
participation  before  randomization.   
 
The following  procedures  will be performed  at the baseline  visit (this visit may take about  4 hours):  
• Review  Inclusion/Exclusion  criteria.   
• Obtain  a medical,  family,  and neurological  history  to assess  for possible  exclusionary  
conditions.  Medical  histories  should  include  baseline  symptoms,  ongoing  illnesses,  other  
chronic  conditions,  surgical  history,  review  of currently  used  medications,  as well as any 
other  important  information  that may affect  the conduc t of the study.  See section  7.1.3.  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  26 of 67 • Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Review  interval  medical  history.  
• Review  adverse  events.  
• Perform  vital sign measurements:  blood  pressure  (syst olic and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6 .   
• Record  weight  (kg) and Body  Mass  Index  (BMI).  
• Perform  an abbreviated  Physical  Examination,  including  visual  field and fall risk 
assessment.   
• Perform  Functional  and Mobility  testing  (6MWT,  TUG,  ABC Scale ). See section  7.1.11 . 
• Perform  nerve  conduction  studies.  See section  7.1.13.  
• Perform  distal  thigh  skin biopsy.  See section  7.1.1 4. 
• Collect  blood  samples  for routine  hematology  panel  blood , basic  metabolic  panel,  
topiramate  level and DNA  analysis  (OPTIONAL) . See section  7.1.1 2.  
• Collect  urine  for a urine  pregnancy  test (pregnancy  test for women  of child-bearing  
potential  only).   
• For women  of childbearing  potential  and sexually  active  males,  review  acceptable  birth 
control  methods  that must  be used  during  the study.   
• Perform  subject  randomization  via interactive  voice  response  system  (IVRS)  and/or  
interactive  web response  system  (IWRS).  See section  4.4.5.  
• Dispense  study  drug.  
• Instruct  subject  about  correct  administra tion and titration  of study  drug.  See section  5.3.2 . 
• Instruct  subject  to bring  unused  study  drug to each  study  visit, and to immediately  report  
any AEs to the Investigator  or Coordinator.   
• Administer  the Neuropathy  Total  Symptom  Score -6 (NTSS -6) to the subject. See section  
7.1.9.  
• Administer  the Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) BPI-DN. See section  
7.1.9 . 
• Perform  clinical  assessment  for suicide  ideation  with the Columbia -Suicide  Severity  Rating  
Scale  (C-SSRS ). See section  7.1.1 5. 
• Complete  the Rapid  Assessment  of Physical  Activity  (RAPA)  Survey.   See section  7.1.17. 
6.5. Visit  03 Week  16 (± 7 days)  
This safety  follow -up visit will occur  within  ± 7 days  of the targeted  visit date.  The following  
procedures  will be performed  at the Week  16 visit (this visit may take about  3 hours):  
• Review  interval  medical  history.   
• Review  adverse  events.  
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Perform  vital sign measurements:  blood  pressure (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6 . 
• Record  weight  (kg) and Body  Mass  Index  (BMI).  
• Record  waist  circumference  (cm).  See section  7.1.7 .  
• Perform  an Abbreviated  Physical  Examination  including  visual  field examination  and 
assessment  for fall risk. 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  27 of 67 • Administer  the Utah  Early  Neuropathy  Scale  (UENS).  See section  7.1.10 . 
• Collect  blood  samples  for safety  monitoring  laboratory  assessments  including  basic  
metabolic  panel,  CBC  and serum  pregnancy  test (pregnancy  test for women  of child-
bearing  potential  only).  (Refer  to University  of Rochester  Medical  Center  Lab Manual  for 
sample  handling  and processing  requirements).  See section  7.1.1 2. 
• Dispense  study  drug.  
• Perform  study  drug reconciliation  and contain er collection.  
• Assess  study  drug compliance.   
• Administer  the Neuropathy  Total  Symptom  Score -6 (NTSS -6) to the subject.  See section  
7.1.9 . 
• Administer  the Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) BPI-DN. See section  
7.1.9 . 
• Administer  the Norfolk  Quality  of Life-Diabetic  Neuropathy  scale  (NQOL -DN). See section  
7.1.19 . 
• Perform  clinical  assessment  for suicide  ideation  with the Columbia -Suicide  Severity  Rating  
Scale  (C-SSRS ). See section  7.1.1 5. 
 
6.6. Visit  04 Week  32 (± 7 days)  
The follow -up visit will take place  within  ± 7 days  of the targeted  visit date.  The following  
procedures  will be performed  at the Week  32 evaluation  visit (this visit may take about  4 hours):  
• Review  interval  medical  history.  
• Review  adverse  events.  
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Perform  vital sign measurements:  blood  pressure  (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6. 
• Record  weight  (kg) and Body  Mass  Index  (BMI).  
• Record  waist  circumference  (cm).  See section  7.1.7 .  
• Perform  an abbreviated  Physical  Examination,  including  visual  field and fall risk 
assessment.  
• Administer  the Utah  Early  Neuropathy  Scale  (UENS).  See section 7.1.10.  
• Perform  Nerve  Conduction  Studies  (NCS).  See section  7.1.1 3. 
• Perform  distal  thigh  skin biopsy.  See section  7.1.1 4.  
• Collect  blood  samples  for OGTT,  CBC,  fasting  basic  metabolic  panel , fastin g insulin,  
fasting  lipid panel,  HgbA1C,  topiramate  level and serum  pregnancy  test for women  of 
child-bearing  potential  only.  See section  7.1.1 2. 
• Perform  Functional  and Mobility  testing  (6MWT,  TUG,  ABC Scale ). See section  7.1.11 . 
• Dispense  study  drug.  
• Perform  study  drug reconciliation  and containe r collection.  
• Assess  study  drug compliance.   
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  28 of 67 • Administer  the Neuropathy  Total  Symptom  Score -6 (NTSS -6) to the subject.  See section  
7.1.9 . 
• Administer  the Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) BPI-DN. See section  
7.1.9 . 
Administer  the Norfolk  Quality  of Life-Diabetic  Neuropathy  scale  (NQOL -DN). See section  
7.1.19 . 
• Perform  clinical  assessment  for suicidal  ideation  with the Columbia -Suicide  Severity  
Rating  Scale  (C-SSRS ). See section  7.1.1 5. 
• Complete  the Rapid  Assessment  of Physical  Activity  (RAPA)  Survey.   See section  7.1.17. 
 
6.7. Visit  05 Week  48 (± 7 days)  
This safety  follow -up visit will occur  within  ± 7 days  of the targeted  visit date.  The following  
procedures  will be performed  at the Week  48 evaluation  visit (this visit may take about  3 hours): 
• Review  interval  medical  history.  
• Review  adverse  events.  
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Perform  vital sign measurements:  blood  pressure  (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6 . 
• Record  weight  (kg) and Body  Mass  Index  (BMI).   
• Record  waist  circumference  (cm).  See section  7.1.7 .  
• Perform  an abbreviated  Physical  Examination,  including  visual  field and fall risk 
assessment.  
• Collect  blood  samples  for safety  monitoring  laboratory  assessments  including  basic  
metabolic  panel,  CBC  and serum  pregnancy  test (pregnancy  test for women  of child-
bearing  potential  only).  See section  7.1.1 2. 
• Dispense  study  drug.  
• Perform  study  drug reconciliation  and container  collection.  
• Assess  study  drug compliance.   
• Administer  the Neuropathy  Total  Symptom  Score -6 (NTSS -6) to the subject.  See section  
7.1.9 . 
• Administer  the Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) BPI-DN. See section  
7.1.9 . 
• Administer  the Utah  Early  Neuropathy  Scale  (UENS).  See section  7.1.10 . 
• Administer  the Norfolk  Quality  of Life-Diabetic  Neuropathy  scale  (NQOL -DN). See section  
7.1.19 . 
• Perform  clinical  assessment  for suicidal  ideation  with the Columbia -Suicide  Severity  
Rating  Scale  (C-SSRS ). See section  7.1.1 5. 
 
6.8. Visit  06 Week  64 (± 7 days)  
The follow -up visit will take place  within  ± 7 days  of the targeted  visit date.  The following  
procedures  will be performed  at the Week  64 evaluation  visit (this visit may take about  4 hours):  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  29 of 67 • Review  interval  medical  history.  
• Review  adverse  events.   
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Perform  vital sign measurements:  blood  pressure  (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6. 
• Record  weight  (kg) and Body  Mass  Index  (BMI).  
• Record  waist  circumference  (cm).  See section  7.1.7 .  
• Perform  an abbreviated  Physical  Examination,  including  visual  field and fall risk 
assessment.   
• Administer  the Utah  Early  Neuropathy  Scale  (UENS).  See section 7.1.10 . 
• Perform  Functional  and Mobility  testing  (6MWT,  TUG,  ABC Scale ). See section  7.1.11 .  
• Perform  Nerve  Conduction  Studies  (NCS).  See section  7.1.1 3. 
• Perform  distal  thigh  skin biopsy.  See section  7.1.1 4. 
• Collect  blood  samples  for OGTT,  CBC,  basic  metabolic  panel , fasting  insulin, fasting  
lipid panel,  HgbA1C , topiramate  level and serum  pregnancy  test for women  of child-
bearing  potential  only.  See section  7.1.1 2. 
• Dispense  study  drug.  
• Perform  study  drug reconciliation  and container  collection.  
• Assess  study  drug compliance.   
• Administer  the Neuropathy  Total  Symptom  Score -6 (NTSS -6) to the subject.  See section  
7.1.9 . 
• Administer  the Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) BPI-DN. See section  
7.1.9 . 
• Administer  the Norfolk  Quality  of Life-Diabetic  Neuropathy  scale  (NQOL -DN). See section  
7.1.19 . 
• Perform  clinical  assessment  for suicidal  ideation  with the Columbia -Suicide  Severity  
Rating  Scale  (C-SSRS ). See section  7.1.1 5. 
• Complete  the Rapid  Assessment  of Physical  Activity  (RAPA)  Survey.   See section  7.1.17. 
 
6.9. Visit  07 Week  80 (± 7 days)  
This safety  follow -up visit will occur  within  ± 7 days  of the targeted  visit date.  The following  
procedures  will be performed  at the Week  80 visit (this visit may take about  3 hours):  
• Review  interval  medical  history.  
• Review  adverse  events.  
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Perform  vital sign measurements:  blood  pressure  (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6 . 
• Record  weight  (kg) and Body  Mass  Index  (BMI).  
• Record  waist  circumference  (cm).  See section  7.1.7 .  
• Perform  an abbreviated  Physical  Examination,  including  visual  field and fall risk 
assessment.   
Administer  the Utah  Early  Neuropathy  Scale  (UENS).  See section  7.1.10 . 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  30 of 67 • Collect  blood  samples  for safety  monitoring  laboratory  assessments  including  basic  
metabolic  panel , CBC,  and serum  pregnancy  test (pregnancy  test for women  of child-
bearing  potential  only).  See section  7.1.12. 
• Dispense  study  drug.  
• Perform  study  drug reconciliation  and container  collection.  
• Assess  study  drug compliance.   
• Administer  the Neuropathy  Total  Symptom  Score -6 (NTSS -6) to the subject.  See section  
7.1.9 . 
• Administer  the Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) BPI-DN. See section  
7.1.9. 
• Administer  the Norfolk  Quality  of Life-Diabetic  Neuropathy  scale  (NQOL -DN). See section  
7.1.19 . 
• Perform  clinical  assessment  of suicidal  ideation  with the Columbia -Suicide  Severity  Rating  
Scale  (C-SSRS ). See section  7.1.1 5. 
6.10.  Visit  08 Week  96 Termination  (± 7 days)  
The final study  treatment  visit will occur  96 weeks  following  baseline.   All assessments  performed  
at the evaluation  visits  will take place.  The investigator  will perform  a complete  physical  
examination.  All study  drug and study  drug packages  will be collected  from the subject  at this visit 
and a final assessment  of study  drug compliance  will be calculated.  The Week  96 visit will occur  
within  ± 7 days  of the targeted  visit date. 
 
The following  procedures  will be performed  at the Week  96 visit (this visit may take about  5 hours): 
• Review  interval  medical  history.  
• Review  adverse  events.   
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Perform  vital sign measurements:  blood  pressure  (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6 . 
• Record  weight  (kg) and Body  Mass  Index  (BMI).  
• Record  waist  circumference  (cm).  See section  7.1.7 .  
• Perform  a general  medical  and detailed  neuromuscular  physical  examination.  See section  
7.1.5 . 
• Administer  the Utah  Early  Neuropathy  Scale  (UENS).  See section  7.1.10 . 
• Perform  Functional  and Mobility  testing  (6MWT,  TUG,  ABC Scale ). See section  7.1.11 .  
• Perform  Nerve  Conduction  Studies  (NCS).  See section  7.1.1 3. 
• Perform  distal  thigh  skin biopsy.  See section  7.1.1 4. 
• Collect  blood  samples  for fasting  basic  metabolic  panel , CBC,  fasting  insulin,  fasting  lipid 
panel,  two-hour OGTT , topiramate  level and HgbA1C . See section  7.1.1 2. 
• Perform  study  drug reconciliation  and container  collection.  
• Assess  study  drug compliance.   
• Administer  the Neuropathy  Total  Symptom  Score -6 (NTSS -6) to the subject.  See section  
7.1.9 . 
• Administer  the Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) BPI-DN. See section  
7.1.9 . 
• Administer  the Norfolk  Quality  of Life-Diabetic  Neuropathy  scale  (NQOL -DN). See section  
7.1.19 . 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  31 of 67 • Perform  clinical  assessment  for suicidal  ideation  with the Columbia -Suicide  Severity  
Rating  Scale  (C-SSRS ). See section  7.1.1 5. 
• Complete  the Rapid  Assessment  of Physical  Activity  (RAPA)  Survey.   See section  7.1.17. 
6.11.  Visit  09 Safety  Assessment  
A safety  call or visit will occur  4 weeks   (+/- 7 days)  following  the last dose  of study  drug.   The 
following  procedures  will be performed  at the safety  assessmen t (this visit may take up to 2 hours) . 
 
If the Site PI determines  a Safety  Call is appropriate  for final safety  assessment , the following  
information  should  be collected;  
 
• Review  interval  medical  history.  
• Review  adverse  events.  
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
 
If the Site PI determines  a Safety  Visit is required  for either  a final safety  assessment  or an 
unsch eduled  safety  visit the following  additional  procedures  can be performed  (optional  safety  
data based  on clinical  judgement  of site PI): 
 
• Review  interval  medical  history.  
• Review  adverse  events.  
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4. 
• Perform  vital sign measurements:  blood  pressure  (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6 . 
• Record  weight  (kg) and Body  Mass  Index  (BMI).  
• Perform  a general  medical  and detailed  neuromuscular  physical  examination.  See section  
7.1.5 . 
• Collect  blood  samples  for basic  metabolic  panel  and CBC . See section  7.1.14 .  
• Perform  clinical  assessment  for suicidal  ideation  with the Columbia -Suicide  Severity  
Rating  Scale  (C-SSRS ). See section  7.1.1 5. 
6.12.  Early  Termination  Visit  (< 30 ± 7 days)  
The following  procedures  will be performed  at the early  termination  visit (this visit may take about  
5 hours) : 
• Review  interval  medical  history.  
• Review  adverse  events.  
• Review  concomitant  medications,  including  all nutritional,  herbal  and alternative  therapies.  
See section  7.1.4 . 
• Perform  vital sign measurements:  blood  pressure  (systolic  and diastolic),  heart  rate 
(beats/minute),  and body  temperature  (°C). See section  7.1.6. 
• Record  weight  (kg) and Body  Mass  Index  (BMI).  
• Record  waist  circumference  (cm).  See section  7.1.7 .  
• Perform  a general  medical  and detailed  neuromuscular  physical  examination.  See section  
7.1.5 . 
• Perform  Functional  and Mobility  testing  (6MWT,  TUG,  ABC Scale). See section  7.1.11 . 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  32 of 67 • Perform  Nerve  Conduction  Studies  (NCS).  See section  7.1.1 3. 
• Perform  distal  thigh  skin biopsy.  See section  7.1.1 4.  
• Collect  blood  samples  for fasting  basin  metabolic  panel , CBC,  fasting  insulin,  fasting  lipid 
panel,  topiramate  level,  two-hour OGTT  and HgbA1C . See section  7.1.1 2. 
• Perform  study  drug reconciliation.  
• Administer  the Neuropathy  Total  Symptom  Score -6 (NTSS -6) to the subject.  See section  
7.1.9 . 
• Administer  the Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) BPI-DN. See section 
7.1.9 . 
• Administer  the Utah  Early  Neuropathy  Scale  (UENS).  See section  7.1.10 . 
• Administer  the Norfolk  Quality  of Life-Diabetic  Neuropathy  scale  (NQOL -DN). See section  
7.1.1 6. 
• Perform  clinical  assessment  for suicidal  ideation  with the Columbia -Suicide  Severity  
Rating  Scale  (C-SSRS ). See section  7.1.1 5. 
• Complete  the Rapid  Assessment  of Physical  Activity  (RAPA)  Survey.   See section  7.1.17. 
6.13.  Early  Termination  and Premature  Withdrawal  
Subjects  have  the right to withdraw  from the study  at any time without  prejudice.   The site 
Investigator  may withdraw  study  drug from a subject  in the study  in the event  of intercurrent  
illness,  adverse  events,  other  reasons  concerning  the health  or well-being of the subject  or other  
administrative  reasons.   Early  termination  will be implemented  in the case  of emergency  
disclosure  of drug treatment  (i.e., unblinding).  NOTE:  All efforts  should  be made  by study  staff  
to encourage  subjects  to return  for follow -up visit(s).  If a subject  withdraws  consent  from  
the study  in writing , no further  contact  can be made.   
 
A subject  may discontinue  study  medication  for the following  reasons:  
 
Administrative  
1. Withdrawal  of consent  
2. Request  of Sponsor  or Principal  Investigator   
3. Request  of primary  care physician  
4. Pregnancy  
5. Subject  deemed  lost to follow  up/failure  to return  
6. Termination  of study  
7. Other   
 
Adverse  Event   
1. Worsening  of the disease  under  study  
2. Worsening  of pre-existing  disease  (other  than disease  under  study)  
3. Intercurrent  illness  
4. Death  
5. Major/clinically  significant  alteration  in laboratory  values  after beginning  study  drug 
6. Suicidali ty based  on the C-SSRS  
7. Other  adverse  event  
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  33 of 67 In the event a participant  discontinues  study  medication  for any reason , every  effort  should  be 
made  to complete  the evaluation  visits at week  32, 64, and 96. An early  termination  visit should  
be completed  for all participants  who are unable  or unwilling  to complete  additional  evaluation  
visits . If a subject  is unable  to return  to the site, or refuses  to complete  all termination  visit 
procedures,  any reasonable  study  procedures  to which  the subject  consents  will be completed.  
 
Should  a scheduled  in-person  visit be impossible,  conduct  as many  of the verbal  assessments  as 
possible,  with special  emphasis  on obtaining  information  on possible  AEs,  and arrange  for return  
of study  drug.  Every  effort  will be made  to determine  the subject’s  health  status  at withdrawal.  
 
Reasons  for early  termination  of the subject  prior  to completion  of the study  must  be stated  
in the CRF and in the site source  documentation  for all study  subjects  who were  enrolled  
in the study.   The CCC  and the IMM must  be informed  within  24 hours  of all study  subjects  
who are withdrawn  due to an adverse  event.  
 
6.13.1.  Premature  Drug  Discontinuation  
Subjects  who prematurely  discontinue  study  drug will be questioned  regarding  reasons  for 
discontinuation.   Subjects  will be encouraged  to restart  study  drug following  the guidelines  in 
section  6.12.2.   
 
6.13.2.  Restarting  Study  Drug  after  Premature  Drug  Discontinuation  
Subjects  who discontinue  study  drug for less than one week  will be asked  to restart  at the prior 
dose.   Those  who failed  to take study  drug for 1-7 days  will be asked  to restart  at the previous  
dose.  Those  not having  taken  study  drug for 8-14 days  will restart  at half of the prior dose.   Those  
not having  taken  study  drug for 15 days  or more  will restart  the titration.   Those  who discontinued  
due to an adverse  event  will restart  at a dose  lower  than the maximally  tolerated  dose  and titrate  
to that dose.   
 
6.13.3.  Missed  Doses  
Subjects  who miss a dose  will continue  the planned  dosing  schedule  and will not supplement  the 
next dose  with that which  was missed.   
 
6.13.4.  On Study/Off -Intervention  Evaluations  
Every  possib le effort  should  be made  by the site PI to encourage  subjects  who are no longer  
taking  study drug to remain  in the study.   They  should  explain  that continued  participation  will 
teach  us more  about  the natural  history  of CSPN  progression,  the impact  of meta bolic 
improvement  and weight  loss on CSPN,  and the clinical  relevance  of IENFD  and other  surrogate  
measures  of CSPN  progression.   
 
When  subjects  decide  to go off the study  drug,  it will be a reportable  event  and the project  
manager  will discuss  the reasons  for this with site staff to learn  the specifics  in each  case  and 
provide  advice  on an individual  basis  about  the best ways  to keep  the subject  engaged  in the 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  34 of 67 project.  These  subjects  and their physicians  will not be told whether  they were  given  topiramate  
or placebo.  
 
6.14.  Off-Study  Requirements  
Adverse  events  will be followed  up to 30 days  after study  completion  (including  early  
termination ) or until the site Principal  Investigator  deems  the condition  to have  resolved  or the 
condition  has stabilized  (whichever  occurs  first).  
6.15.  Pregnancy   
Women  who become  pregnant  while  in the study  will have  the study  drug withdrawn  immediately,  
will be asked  to return  for a final in-person  evaluation,  and will be followed  according  to adverse  
event  reporting  procedures  until birth or conclusion.  Generally,  follow -up will not exceed  8 weeks  
following  the estimated  delivery  date.   
6.16.  Diabetes  
Patients  who meet  ADA criteria  for diabetes  at screening  will be excluded.   Those  who develop  
diabetes  during  the course  of the study  may continue  in the study.   However,  in the event  a 
participant  is found  to have  diabetes  on follow  up metabolic  testing,  their primary  care provider  
will be notified.  
 
 
7. SPECIAL  INSTRUCTIONS  AND  DEFINITIONS  OF EVALUATIONS  
7.1.1.  Informed  Consent  
Written  informed  consent  will be obtained  from each  participant  before  any study -specific  
procedures  or assessments  are performed  and after the aims,  methods,  anticipated  benefits,  and 
potential  hazards  are explained.  The participant’s  willingness  to participate  in the study will be 
documented  in writing  in a consent  form,  approved  by the NeuroNEXT  CIRB,  which  will be signed  
by the participant  with the date of that signature  indicated.  The investigator  will keep  the original  
consent  forms  and copies  will be given  to the participants.  It will also be explained  to the 
participants  that they are free to refuse  entry  into the study  and free to withdraw  from the study  at 
any time without  prejudice  to future  treatment.  Written  and/or  oral information  about  the study  in 
a language  understandable  by the participant  will be given  to all participants.  HIPAA  guidelines  
for confidentiality  and the principles  of medical  ethics  will be adhered  to during  the study.   
 
7.1.2.  Protocol  Violations  
The site monitor  is responsible  for collection  of all protocol  deviations  that occur  during  the course  
of the study  to ensure  proper  reporting  in the clinical  study  report.   
 
Generally,  any activity  that is not performed  as outlined  in the protocol  should  be categorized  as 
a ‘Protocol  Deviation ’.  Missed  visits and any procedures  not performed  (not attempted)  for 
reasons  other  than illness,  injury  or progressive  disability  (i.e., subject  is physically  unable  to 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  35 of 67 perform  test) will be reported  as protocol  deviations.  Procedures  or visits  not performed  due to 
illness,  injury  or disability,  including  procedures  that were  attempted  but failed  (i.e., blood  samples  
unable  to be drawn  after multiple  attempts,  or weight  unable  to be obtained  due to subject  
immobility)  will not be reported  as protocol  deviations.  Deviati ons fall into two categories,  ‘major ’ 
and ‘minor ’, and are defined  as follows:  
 
Major:  Any deviation  that impacts  safety,  welfare,  or rights  of a study  subject,  or impacts  the 
primary  outcome  of the study  (safety  assessments).  Examples  include:  Informed  Consent  issues  
affecting  a subject’s  rights,  Inclusion/Exclusion  violations,  Missed  Asse ssments  affecting  safety  
endpoints,  Study  Drug  Administration  that affects  a study  endpoint  or the subject’s  welfare.  A 
major  deviation  is also termed  a protocol  violation.  
 
Minor:  Any deviation  that does  not fall within  the above  category.  Examples  includ e: out of 
window  or missed  study  assessments  that do not affect  study  endpoints  or the subject’s  welfare.   
 
7.1.3.  Medical  History  
A complete  medical  history  including  lifestyle  questions  (i.e., tobacco  and alcohol  use) will be 
obtained  at screening  and prior to randomization.   
 
7.1.4.  Concomitant  Medications/Treatments  
All concomitant  medications  must  be recorded,  including,  but not limited  to all vitamins,  
supplements,  nutritional,  herbal  and alternative  therapies.  
 
7.1.5.  Physical  Examination  
A general  medical  and detailed  neuromuscular  physical  examination  will be performed  in order  to 
exclude  medical  conditions  precluding  participation,  and to confirm  symptoms  consistent  with 
distal  symmetric  polyneuropathy.  The neurological  examination  will include  a baseline  
assessment  of visual  fields.   
 
7.1.6.  Vital  Signs  
Vital signs  will be obtained  after the subject  has been  sitting  for five minutes.   Vital signs  include  
blood  pressure  (systolic  and diastolic),  heart  rate (beats/minute),  and body  temperature  (°C). 
 
7.1.7.  Waist  Circumference  
Waist  circumference  will be measured  in centimeters  (cm) while  standing.   Measurement  will be 
performed  at the level of the iliac crest after expiration.  
 
7.1.8.  Electrocardiogram  (ECG)  
An electrocardiogram  (ECG)  will be performed  to exclude  a baseline  prolonged  QTc interval.  
ECGs  with QTc interval  more  than 430 ms in men,  or 450 ms in women  will be reviewed  at each  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  36 of 67 site. Participants  with QTc more  than 450 ms in men,  or 470 ms in women  will be considered  
screen  failures.  Electrocardiogram’s  are not required  to be reviewed  by the site cardiologist.   
7.1.9.  Neuropathy  Symptom  Assessment  
Neuropathy  Total  Symptom  Score  -6 (NTSS -6) 53 is a brief inventory  of neuropathy  symptoms  
that has demonstrated  reliability  and validity  in diabetic  neuropathy.   
 
Brief Pain Inventory  – Diabetic  Neuropathy  (BPI-DN) 54,55 is a validated  pain inventory  that 
assesses  pain severity  related  to CSPN.  
 
7.1.10.  Utah  Early  Neuropathy  Scale  (UENS)  
Utah  Early  Neuropathy  Scale  (UENS)  48 will be performed  by the investigator  to confirm  diagnosis  
and exclude  patients  with severe  neuropathy.  
 
7.1.11.  Functional  and Mobility  Testing  
Functional  and mobility  testing,  fitness  and proactive  balance  will be assessed  because  balance  
and fall risk are major  clinically  relevant  outcomes  for patients  with CSPN.    
o A 6-minute  walk test (6MWT)  will be performed  on a standard  course  that will be used 
throughout  the study.   The 6MWT  has demonstrated  reproducibility  in obese  participants56 
and has been  shown  to correlate  with intermuscular  adipose  tissue,  a depot  of adipocytes  
related  to insulin  resistance  and increased  in patients  with metabolic  syndrome57.    
o A Timed  up and Go (TUG)  will be performed  as a measure  of proactive  balance  and 
fitness.   TUG  times  are normally  distributed,  resistant  to ceiling  effects58 and are reduced  
in patients  with neuropathy  in the setting  of diabetes  relative  to control participants59.  
Among  commonly  employed  fall risk assessments,  the TUG  had the highest  diagnostic  
accuracy60. 
o The Activities -specific  Balance  Confidence  (ABC)  Scale.   The ABC scale  is a self-
administered  instrument  assessing  balance  and gait confidence.89  
 
7.1.12.  Laboratory  Evaluations  
Clinical  laboratory  evaluations  for the study  will be analyzed  by the NeuroNEXT  central  laboratory  
at the University  of Rochester.  Refer  to the University  of Rochester  Medical Center  Lab Manual  
for sample  handling  and processing  requirements.   
 
The following  laboratory  assessments  will be performed  throughout  the study:  
• Safety  monitoring  laboratory  tests:  
o Complete  Blood Count (CBC)  
o Basic  Metabolic  Panel  (BMP)  including  Sodium,  Potassium,  Chloride,  Carbon  
Dioxide,  Urea  Nitrogen,  Glucose,  Creatinine,  Calcium,  and Anion  Gap (optional).  
o Hematology  Panel  
o Serum  Pregnancy  Test (for women  of child-bearing  potential  only)  
o Urine  Pregnancy  Test (for women  of child-bearin g potential  only)  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  37 of 67 • Baseline  metabolic  monitoring  laboratory  tests.  These  are intended  to assess  the 
metabolic  effects  of therapy  and to confirm  the presence  of metabolic  syndrome  for 
inclusion  criteria  and evaluation  throughout  the study : 
o Fasting  Insulin   
o Fasting  Lipid  Panel including  Cholesterol,  Triglycerides,  Calculated  LDL 
Cholesterol,  and HDL Cholesterol.  
o 2-hour Oral Glucose  Tolerance  Test (OGTT)  using  a 75g anhydrous  dextrose  oral 
load with the first blood  draw  (pre-dextrose)  prior to 10 am. The secon d draw  will 
be 2 hours  post dextrose.   The subject  will remain  sedentary  during  the following  
two hours.  
o HgbA1C  
• Laboratory  evaluation  for additional  causes  for neuropathy:  
o Vitamin  B12  
o Serum  Immunofixation  
• Serum  topiramate  levels  will be measured  at Baseline  and weeks  32, 64, and 96 (or ET) 
in order  to assess  for compliance  and treatment  crossover.   
 
Participants  will be asked  to hold their morning  dose  of study  medication  until after the 
blood  draw  at weeks  32, 64, 96/ET.   The date and time of last dose of study  drug will be 
recorded.    If the participant  does  not hold the prior dose,  the topiramate  level should  still 
be obtained.    
 
Topiramate  laboratory  kits, shipping  materials,  and requisitions  will be provided  by Utah .  
The sample  will be obtained  in a red collection  tube with serum  separated  by centrifuge  
within  2 hours.   Serum  will be placed  in the transport  vial and refrigerated  prior to being  
placed  on a cold pack for shipment .   The sample  will be returned  to Utah  with the skin 
biopsy  sample .  Samples  should  be received  by Utah  cool (not frozen).   The results  will 
be made  available  to the DSMB.  
• DNA  sample  (OPTIONAL)  
DNA  samples  can be collected  at Baseline  using  supplies  provided  by URMC.   Centrifuge  
the EDTA  tube at 1500  RPM  for 15 minutes.    The buffy  coat will be transferred  into 
cryovials  and stored  at -80C.   At the end of the enrollment  period,  sites will batch  ship all 
the buffy  coat samples  to Utah  with shipment  kit and air bills provided.  
 
 
All clinical  and laboratory  evaluations,  proce dures  related  to inclusion/exclusion  criteria,  or 
assessments  performed  during  treatment  will be reviewed,  initialed  and dated  by the Principal  
Investigator  or the individual (s) specifically  designated  by the investigator  on the DOR  log. The 
Investigator  must indicate  if out of range  lab values  are Clinically  Significant  (CS) or Not Clinically  
Significant  (NCS)  on the lab report.  
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  38 of 67 7.1.13.  Nerve  Conduction  Studies   
Nerve  conduction  studies  (NCS)  will be performed  at baseline  and each  evaluation  visit. NCS  will 
be performed  on the left leg unless  focal  skin or orthopedic  lesions  preclude  safe or accurate  
performance  of NCS  in this limb,  in which  case  NCS  will be performed  on the right leg. NCS  of 
the Sural  sensory  and Peroneal  motor  nerves  with distal  latency/conduction  velocity,  Peroneal  
motor  conduction  velocity  in the leg segment  (between  the ankle  and knee).    
 
Definition  of CSPN:   For the purposes  of CSPN  diagnosis,  an absent  or low amplitude  sural  
sensory  response  is required  (as defined  below).   
 
Detailed  protocol:   NCS  will be performed  using  standard  techniques.   Unless  there  is a local 
process  such  as a skin lesion,  prior traumatic  injury,  history  of radiculopathy  etc. Skin temperature  
must  be maintained  > 31°C.  Temperature  should  be recorded  from the dorsal  foot and 
documented.   T 
 
The sural  sensory  response  will be performed  in an antidromic  fashion  with stimulation  14 cm 
proximal  to the recording  electrode,  which  will be placed  posterior  to the lateral  malleolus.  
Subsequently,  two additional  responses  will be recorded  using  a sweep  speed  of 2 msec/division  
and an appropriate  sensitivity  setting.   Three  responses  will be averaged  using  the same  sweep  
and gain settings,  from which  amplitude  and distal  latency  will be derived.    
 
The peroneal  motor  response  will be recorded  from the EDB muscle  with stimulation  9 cm 
proximally  at the ankle,  and at the level of the fibular  head.  Obtain  a single  waveform  at each  
simulation  site, marking  the onset  latencies  and baseline  to peak  amplitudes.   The conduction  
velocity  will be calculated.  The minimal  F wave  latency  will be measured  using  a sensitivity  of 
200-500 uV/division  and at least  10 stimuli.  
 
The waveforms  will be uploaded  to the central  NCS  laboratory  at the University  of Utah  for 
immediate  revie w.  This review  will ensure  adequate  adherence  to protocol  (temperature,  
stimulation  location,  averaging)  and technical  quality  (baseline  stability,  absence  of artifact).   If 
after review,  technical  deficiencies  are noted,  the site will be notified  and the selected  NCS  will 
be repeated51.   
 
 
7.1.14.  Skin  Biopsy  
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  39 of 67 The left leg is the preferred  site for skin biopsy.   The left lower  extremity  will be evaluated  by study  
staff to rule out previous  surgery  at the hip or proximal  to the knee.  The site of biopsy  should  not 
have  scarring , rash,  burns,  significant  edema,  or tattoos.  If any of these  conditions  are present,  
the right leg should  be similarly  evaluated , and biopsied,  if appropriate .   All biopsies  should  be 
performed  from the same  side throughout  the study, unless  reasonable  justification  is 
documented  (ie: trauma  or surgery to previously  used  side).   
 
A 3mm  punch  biopsy  will be taken  from the selected  the biopsy  site using  local anesthesia  
(lidocaine  with epinephrine ) using  standardized  techniques.   The punch  will be placed  in fixative  
and shipped  overnight  courier  to the Utah  Cutaneous  Nerve  Laboratory , where  the tissue  will be 
processed  and stained  using  PGP9.5  and intraepidermal  nerve  fiber density  (IENFD)  measured62. 
 
 
Details  of the skin biopsy  procedure,  sample  handling,  processing  and shipping  are available  in 
the reference  manual  for skin biopsy .  
 
 
7.1.14.1.   Distal  Thigh  Skin  Biopsy  
 
A distal  thigh  skin biopsy  is collected  at the following  visits:  Baseline  (Visit  02), Week  32 (Visit  
04), Week  64 (Visit  06), and Week  96 (Visit  08/Termination)  and/or  Early  Termination.    
A 3mm  punch  biopsy  will be taken  from the distal,  lateral  thigh  10 cm distal  to superior  margin  of 
the patella .    
 
Refer  to the Reference  Manual  for skin punch  biopsy.    
7.1.15.  Columbia -Suicide  Severity  Rating  Scale  (C-SSRS ) 
The C-SSRS  is a suicidal  ideation  rating  scale.  It measures  a Subject’s  degree  of suicidal  ideation  
on a scale  ranging  from wishing  to be dead  without  an active  plan to active  suicidal  ideation  with 
a specific  plan and intent  to die. Only investigators  who have  been  fully trained  in the 
administration  of the C-SSRS  will assess  subject  suicidality.  As part of training,  investigators  are 
prepared  to respond  to and manage  instances  in which  patients  express  suicidal  ideat ion or 
exhibit  suicidal  behavior.  
 
7.1.16.  The Norfolk  Quality  of Life – Diabetic  Neuropathy  (NQOL -DN) Scale    
Patient  reported  neuropathy  related  QOL.  The NQOL -DN is a validated  neuropathy  specific  QOL  
measure.   Factor  analysis  has been  used  to group  NQOL -DN items  into 6 subscores:  symptoms,  
autonomic,  small  fiber,  large  fiber,  and activities  of daily living27.   
 
7.1.17.  The Rapid  Assessment  of Physical  Activity  (RAPA)  Survey  
The RAPA  is a validated  patient  reported  survey  that quantifies  the intensity  and frequency  of 
aerobic  and strength  activity .90   The RAPA  is included  in order  to assess  the degree  of exercise  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  40 of 67 and physical  activity  between  the treatment  groups.   This is important  because  intensive  exercise  
programs  may impact  the natural  history  of CSPN  associate d with prediabetes.  
 
7.1.18.  Subject  Adherence  Assessments  
At each  study  visit, the site Investigator  and/or  Study  Coordinator  will assess  the subject’s  
compliance  with the study  requirements  by performing  study  drug reconciliation  and collecting  
study  drug containers.   This will also include  reviewing  protocol  compliance,  including  use of study  
drug and concomitant  medications.  If applicable,  subjects  who fail to comply  with the study  
requirements  may be removed  from the study.  
 
The site Investigator  and/or  Study  Coordinator  will conduct  monthly  telephone  calls between  clinic  
visits  (i.e.: between  Baseline  and Week  16 calls should  occur  at Week  4, Week  8, and Week  12) 
to encourage  protocol  compliance  and enhance  retention.    
 
7.1.19  Optional  Tissue  Banking  
 
DNA  samples  will be collected  at Baseline  using  supplies  provided  by URMC.   Centrifuge  the 
EDTA  tube at 1500  RPM  for 15 minutes.    The buffy  coat will be transferred  into cryovials  provided  
by Utah  and stored  at -80C.   At the end of the enrollment  period,  sites will batch  ship all the buffy  
coat samples  to Utah  with shipment  kit and air bills provided.  
 
Skin biopsy  tissue  collected  for IENFD  testing  for will be stored  at the Utah  Cutaneous  Nerve  Lab 
until study  closure.   Samples  from participants  who consent  to long-term tissue  storage  will be 
placed  in long-term tissue  banking  and the rest will be destroyed.  
 
The DNA  and tissue  bank  will be located  in the laboratory  of Rob Singleton , MD, at the University  
of Utah.    Participants  can withdraw  consent  to bank  their samples  by notifying  their CSS 
investigat or.   Banking  preferences  will be entered  into the EDC  by the CSS staff.   At the end of 
the study,  DNA  or tissue  in the bank  will be destroyed  if participants  opt out of banking  at any time 
during  the study  or do not mark  and initial  their preference  on the consent  form.  
 
 
 
8. MANAGEMENT  OF ADVERSE  EVENTS  
Extensive  data regarding  safety  and adverse  events  are available  from clinical  trials  of topiramate  
for epilepsy  and episodic  migraine.  The dose  of topiramate  to be used  in the TopCSPN  Study  is 
similar  to that used  for episodic  migraine  (50-200mg  daily).   Adverse  events  observed  in 
randomized  trials  for migraine  will be summarized65.  Following  this summary,  potentially  
significant  adverse  events  observed  at higher  doses  will be listed.   
 
When  topiramate  must  be discontinued  for participant  safety , the dose  can be stopped  
immediately  or titrated  down   based  on the clinical  judgement  of the site investiga tor.  
 
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  41 of 67 Adverse  Events  Observed  at 100 mg daily of topiramate : 
• Anorexia .  Loss  of appetite  is one of the mechanisms  contributing  to weight  loss. Most  
commonly  anorexia  is mild.   In subjects  complaining  of intolerable  anorexia , the dose  will 
be tapered  to the maximal  tolerated  dose.  
• Fatigue . Subjects  complaining  of intolerable  fatigue  will be asked  to taper  the dose  to the 
maximum  tolerated.  
• Memory  Problems . Topirmate  may cause  confusion,  psychomotor  slowing,  poor 
concentration,  or memory  loss.  These  symptoms  are more  commonly  observed  with rapid  
dose  escalation.  Patients  complaining  of intolerable  memory  problems,  or those  observed  
to have  cognitive  dysfunction  sufficiently  significant  to warrant  dose  modification  in the 
opinio n of the PI will taper  their dose  to that maximally  tolerated.  
• Nausea . Subjects  complaining  of intolerable  nausea  will be asked  to taper  the dose  to the 
maximum  tolerated.  
• Paresthesias .  Paresthesias  are typically  mild and uncommonly  lead to discontinuatio n.  
In the setting  of this study,  paresthesias  may also be related  to the underlying  disease  
(CSPN),  or nerve  regeneration.   There  are no data suggesting  topiramate  causes  or 
worsens  peripheral  neuropathy.   Subjects  experiencing  increased  paresthesias  will be 
encouraged  to continue  to participate  unless  the symptom  is severe  enough  in the opinion  
of the PI to warrant  dose  reduction.   
 
Potentially  serious  adverse  events  noted  in the package  insert  include:  
• Glaucoma.  Topiramate  has been  reported  to cause  acute  myopia  associated  with 
secondary  angle  closure  glaucoma.  Symptoms  typically  occur  within  1 month  of initiating  
therapy,  and include  decreased  visual  acuity  and ocular  pain.  Ophthalmologic  findings  can 
include  myopia  and ocular  hyperemia  (redness).   Mydriasis  may or may not be present.  
Visual  acuity  will be assessed  at each  visit and subjects  with reduced  acuity,  ocular  pain,  
or ocular  hyperemia  will discontinue  medication  and be immediately  referred  for 
ophthalmologic  examination.  
• Kidney stones.  1.5% of adults exposed to topiramate during its adjunctive epilepsy therapy 
development reported the occurrence of kidney stones, an incidence about 2 to 4 times 
greater than expected in a similar, untreated population. Carbonic anhydrase inhibitors 
(Topiramate , but also zonisamide, acetazolamide or dichlorphenamide) can promote 
stone formation by reducing urinary citrate excretion and by increasing urinary pH.  
• Metabolic acidosis . Hyperchloremic, non -anion gap, metabolic acidosis (i.e., decreased 
serum bicarbona te below the normal reference range in the absence of chronic respiratory 
alkalosis) is caused by renal bicarbonate loss due to the inhibitory effect of topiramate  on 
carbonic anhydrase. Renal disease, severe respiratory disorders, status epilepticus, 
diarrhea, and ketogenic diet may increase this risk. Symptoms may include  
hyperventilation, fatigue, anorexia, or rarely cardiac arrhythmias or stupor. Serum 
electroly tes including bicarbonate will be measured at eac h study visit.  Subjects with a 
total bicarbonate of < 17 mEq/L and a > 5 mEq/L decrease from pretreatment will 
discontinue treatment.  
• Oligohidrosis  (decreased  sweating)  and subsequent  loss of temperature  regulation  with 
hyperthermia  has been  reported  in adults,  especially  in combination  with carbonic  
anhydrase  inhibitors  and anticholinergic  medications.   Subjects  complaining  of significant  
reduction  in sweating  will taper  medication  to the maximum  tolerated  dose.  
• Visual  field defects  (independent  of elevated  intraocular  pressure)  have  been  reported  in 
clinical  trials  and in postmarketing  experience.   Visual  fields  will be assessed  at each  study  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  42 of 67 visit.  Patients  observed  to have  new visual  field abnormalities  will be referred  for 
ophthalmologic  examination  and medication  will be discontinued.  
 
8.1. Pregnancy  
Pregnancy  itself is not regarded  as an AE unless  there  is a suspicion  that the study  drug may 
have  interfered  with the effectiveness  of a contraceptive  medication.  However,  the outcome  of all 
pregnancies  that occur  during  paternal  or maternal  exposure  to study drug (spontaneous  
miscarriage,  elective  termination,  normal  birth or congenital  abnormality)  must  be followed  up and 
documented  even  after the subject  has been  withdrawn  from the study.  All reports  of congenital  
abnormalities/birth  defects  are SAEs.  Spontaneous  miscarriages  should  also be reported  and 
handled  as SAEs.  Elective  abortions  without  complications  should  not be handled  as AEs.  All 
outcomes  of pregnancy  must  be reported  to the Coordination  Center.   
 
 
9. PROTOCOL  AMENDMENTS  AND  STUDY  TERMINATION  
All revisions  and/or  amendments  to this protocol  must  be approved  in writing  by the Sponsor  and 
the CIRB.  The Investigator  will not make  any changes  to the conduct  of the study  or the protocol  
without  first obtaining  written  approval  from the Sponsor  and the CIRB,  except  where  necessary  
to eliminate  an apparent  immediate  hazard  to a study  subject.  
The Sponsor  and NeuroNEXT  Network  reserve  the right to discontinue  the study  at a clinical  study  
site(s)  for safety  or administrative  reasons  at any time.  Should  the study  be terminated  and/or  the 
clinical  study  site closed  for any reason,  all documentation  and study  drug pertaining  to the study  
must  be returned  to the Sponsor  or its representative.  
 
 
10. STATISTICAL  CONSIDERATIONS  
The NeuroNEXT  Data  Coordinating  Cente r has developed  a statistical  analysis  plan,  in 
collaboration  with the protocol  principal  investigator  and protocol  steering  committee.  
 
a. General  considerations . Univariate  summaries  will be provided  for all randomized  subjects  and 
by treatment  group.  Transformations  will be considered  for continuous  variables  exhibiting  
substantial  skewness.  Analyses  of topiramate ’s effect  will be conducted  according  to randomized  
treatment  assignment  in accordance  with the intent -to-treat principle.   
 
b. Strategy  for evaluating  the Co-Primary  Endpoints  in Aim 1. Analyses  of the effects  of topiramate  
on the co-primary  endpoints  will be interpreted  from two perspectives.  From  a scientific  
investigational  perspective,  IENFD  and NQOL -DN will be viewed  as representing  separ ate 
outcome  domains,  and the hypotheses  of treatment  effects  on these  outcomes  will be considered  
conceptually  distinct.  Because  positive  findings  from this early -phase  trial will be subjected  to 
conformation  in a subsequent  pivotal  trial, the scientific  hypotheses  of treatment  effects  on the 
conceptually  distinct  co-primary  endpoints  will be tested  on a comparison -wise basis  without  
multiple  comparison  adjustment  in order  to enhance  statistical  power  74,75. From  a decision -
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  43 of 67 theoretic  perspective,  the result s of this early -phase  clinical  trial will be applied  to determine  
whether  to proceed  to a larger  pivotal  trial with a definitive  clinical  endpoint.  Proceeding  to a full-
scale  trial will be deemed  appropriate  if the present  trial demonstrates  that topiramat e has a 
benefit  based  on either  IENFD  or NQOL -DN and does  not have  an adverse  effect  the other  
outcome.  Because  this choice  represents  a single  decision  point,  a single  global  decision  rule to 
control  the risk of inappropriately  proceeding  to a full-scale  trial will be applied.  The analyses  of 
the effect  of topiramate  on the IENFD  and NQOL -DN as distinct  endpoints  are described  first, 
followed  by a global  strategy  for deciding  whether  to proceed  to a full-scale  trial.   
c. Analysis  of Co-Primary  Endpoints . We hypothesize  that topiramate  will reduce  the rate of 
deterioration  of IENFD  over the full follow -up period.  Hence  the primary  analysis  of the IENFD  will 
compare  the mean  IENFD  slope  between  the treatment  and control  groups  under  a longitudinal  
model  with fixed  effects  for baseline  IENFD,  age, baseline  BMI randomization  stratification  group,  
follow -up time (as a continuous  variable),  and the interaction  between  treatment  assignment  and 
follow -up time.  Inclusion  of baseline  IENFD  as a covariate  will increas e statistical  power  in a 
similar  fashion  as adjustment  for the baseline  level of the outcome  in a conventional  analysis  of 
covariance.  Expressed  mathematically,  the longitudinal  model  for IENFD  is: Yit = α0 + Yi0 β0 + Age 
β1 + [BMI Group]  β2 + Yi0 × time ij × β3 + Ti β4 + time it β5 + Ti × time it β6 + εit, Var()=Σ,   i = 1, 2, .., N, 
t = 0, 1, 2, 3, where  Yit denotes  the IENFD  measurement  for patient  i at visit t, with t = 0 
representing  the baseline  visit so that Yi0 is the baseline  IENFD,  Ti denotes  the randomized  
treatment  group  for the ith patient  (with  Ti = 1 for the topiramate  group,  and Ti = 0 for the control  
group),  time it denotes  the time of the tth IENFD  measurement  for patient  i, Ti × time it denotes  the 
treatment  by time interaction,  and the εit deno te residuals  of the IENFD  measurements  which  are 
assumed  to be normally  distributed  with a covariance  matrix  Σ which  is described  below.  The 
coefficient  β6 represents  the effect  of the topirimate  treatment  on the mean  IENFD  slope  over 
time.   We will use a general  unstructured  covariance  model  for Σ 76so that the full model  
represents  a special  case  of the linear  mixed  model  76,77 that allows  for all possible  correlations  
among  the residuals  among  the IENFD  measurements.  When  the number  of time points  is small  
relative  to the number  of subjects  as is the case  for IENFD  in this proposal,  the general  
unstructured  covariance  model  is widely  used  in randomized  trials  because  it provides  essentially  
identical  statistical  power  to that obtained  under  less general  covariance  models  while  avoiding  
the need  for post-hoc modifications  to satisfy  modeling  assumptions76. Estimates  of the model  
coefficients  and standard  errors  will be obtained  by restricted  maximum  likelihood  estimation  
(RMLE)78.  
 
Topiramate  may have  direct  effects  on QOL  that are independent  of CSPN  progression  and 
which  may occur  shortly  after treatment  initiation,  as well as longer  term effects  that result  from 
effects  of topiramate  on neuropathy  progression.  Accordingly,  the primary  analy sis of the NQOL -
DN will compare  the total mean  change  in the NQOL -DN from baseline  to 2 years  between  the 
treatment  and control  groups  under  a longitudinal  model  that includes  linear  spline  terms  to allow  
separate  mean  slopes  during  the first 12 weeks  after randomization  and from 12 weeks  to the 
end of follow -up.  Age, baseline  BMI group  and baseline  NQOL -DN will be treated  as a covariates  
to increase  statistical  power.  In addition  to the primary  comparison  of the total mean  change  in 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  44 of 67 the NQOL -DN to 2 years , linear  contrasts  will be constructed  to estimate  the effect  of the treatment  
on the early  change  in the NQOL -DN to 16 weeks , and on the longer -term NQOL -DN slope  after 
16 weeks . Expressed  mathematically,  the mixed  effects  model  for the NQOL -DN is: Yit = α0 + Yi0 
β0 + Age β1 + [BMI Group]  β2 + Yi0 timlo it β3 + Yi0 timhi it β4 + Ti β5 + timlo it β6 + timhi it β7 + Ti × timlo it 
β8 + Ti × timhi it β9 + εit,   Var( it)=Σ,  i = 1, 2, .., N, t = 0, 1, 2, …, 6, where  Yit denotes  the NQOL -DN 
measurement  of the ith patient  at visit t, timlo it = min(0,  time it – 16 weeks ) and timhi it = max(0,  time it 
– 16 weeks ) represent  linear  spline  terms  in follow -up time,  and the remaining  terms  are 
analogous  to those  defined  in the model  for the IENFD  described  above.  Accounting  for separate  
slopes  in the first 16 weeks  and the subsequent  80 weeks , the primary  linear  contrast  defining  
the treatment  effect  on the mean  change  to 2 years  is 4 × β8 + 20 × β9. Due to the relatively  large  
number  (6) of follow -up measurement  times  for the NQOL -DN, an unstructured  covariance  model  
may lead to inefficient  estimation76, and a relatively  parsimonious  covariance  model  will be used  
to limit the number  of unknown  parameters  to be estimated76. Standard  covariance  models  to be 
considered  include  models  with random  intercepts  and slopes  combined  with an autoregressive  
or Toeplitz  covariance  matrix  for the residuals  around  the underlying  trajectories79-81. The 
covariance  model  will be selected  from a pre-specified  collection  of potential  models  by comparing  
BIC statistics  under  maximum  likelihood  estimation81. After  selection  of the covariance  model,  
final statistical  inferences  will be performed  using  restricted  maximum  likelihood  estimation  as in 
the analyses  of the IENFD  outcome.     
 
d. Missing  Data. Because  statistical  inference  is based  on restricted  maximal  likelihood  (REML)  
estimation,  the longitudinal  analyses  described  above  will remain  unbiased  in the presence  of 
missing  data which  follows  a missing  at random  mechanism82; sensitivity  analyse s will be 
conducted  using  multiple  imputation  of missing  data83 under  imputation  models  which  incorporate  
auxiliary  variables  to account  for predictors  of missingness  and/or  the variables  being  analyzed  
beyond  those  in the analytic  model.   
 
e. Statistical  Power  for Separate  Analyses  of the Co-Primary  Endpoints . Statistical  power  for 
IENFD  was estimated  by first fitting  a mixed  effects  model  to the first 2 years  of follow -up for 116 
subjects  from the Utah  Diabetic  Neuropathy  Study  natural  history  cohort  with baseline  MNSI  ≥ 3, 
indicating  the presence  of neuropathy  symptoms.   This cohort,  as described  in the preliminary  
data,  excluded  patients  with longstanding  neuropathy  and is thus appropriate  given  the 
phenotypic  similarity  with CSPN.  This analysis  yielded  variance  components  for IENFD  
trajectories  over time and within -subject  residuals.  A design  matrix  was then constructed  for the 
planned  measurement  schedule  for the topiramate  trial with IENFD  measurements  at baseline  
and weeks  32, 64 and 96 but with 4% loss-to-follow -up every  32 weeks  for a total 12% loss-to-
follow -up over 96 weeks . Using  this design  matrix  and the variance  components  estimated  from 
the preliminary  data,  125 randomized  subjects  will provide  80% power  with 2-sided  α=0.05  to 
detect  a difference  in mean  IENFD  slope  between  the treatment  and control  groups  of 0.47 
fibers/mm/year.  An effect  of 0.47 fibers/mm/year  represents  a reduction  in the mean  slope  from -
0.68 fibers/mm/year  observed  in our preliminary  data to -0.21 fibers/mm/year.  This projected  
effect  size is conservative  given  preliminary  data that successful  intervention  may result  in 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  45 of 67 improvement  in IENFD  rather  than just slowing  of its rate of decline10,12,13.  Statistical  power  for 
the NQOL -DN was estimated  based  on an assumed  SD for change  in the NQOL -DN score  over 
2 years  of 16.4 points,  which  conservatively  allows  for a 10% higher  SD than the SD of 14.9 points  
reported  for the change  in the NQOL -DN in Boyd  et al24. If the correlation  between  baseline  and 
follow -up assessments  is ≤ 0.60,  125 subjects  with 12% loss to follow -up will provide  80% power  
with 2-sided  α=0.05  to detect  a mean  difference  of 7.9 points  between  the treatment  and control  
groups  over 96 weeks  after adjustment  for the baseline  NQOL -DN. This represents  a difference  
of 4.0 points  per year.  This power  calculation  is conservative,  as the multiple  repeated  QOL  
measurements  in the study  design  will provide  greater  precision  than the simplified  ANCOVA  
based  on a single  follow -up time considered  in this power  calculat ion.  
 
f. Decision  for proceeding  to a full-scale  trial (“Go/No -Go” Algorithm) . A full-scale  trial will be 
justified  if topiramate  is demonstrated  to be superior  to placebo  for either  IENFD  or NQOL -DN, 
and non-inferior  for both of these  outcomes.  We estima ted non-inferiority  margins  of up to 0.50 
fibers/mm/year  for the IENFD  slope  and up to an average  of 5 points  per year for the NQOL -DN. 
A failure  to proceed  to the full-scale  trial would  be problematic  if there  is a treatment  benefit  of 
0.50 fibers/mm/year  for the IENFD  or of an average  of 5.0 points  per year for the NQOL -DN and 
the treatment  does  not have  an adverse  effect  on the other  outcome.  Based  on these  conditions,  
the following  global  decision  rule was developed:  Proceed  to the full scale  trial if either:  
1. The comparison  of randomized  groups  favors  topiramate  by at least  0.30 fibers/mm/yr  for 
IENFD  and favors  the placebo  by no more  than 2.70 points  per year for the NQOL -DN, or  
2. The comparison  of randomized  groups  favors  topiramate  by at least  2.97 points per year for 
the NQOL -DN & favors  the placebo  by no more  than 0.22 fibers/mm/yr  for the IENFD.  
  
Given  the previously  stated  assumptions  for the analyses  of IENFD  and NQOL -DN as separate  
endpoints,  and assuming  a Pearson  R of -0.30 between  the IENFD  and QOL -DN based  on Boyd  
et al24, numerical  integration  of the bivariate  normal  distribution  implies  that this global  decision  
rule has a Type  1 error  ≤ 5% for an inappropriate  recommendation  to proceed  to a full scale  trial 
given  inferiority  for at least  on outcome  or absence  of superiority  for both outcomes,  and Type  2 
error  ≤ 18% for failure  to recommend  proceeding  to the full scale  trial when  the stated  criteria  for 
superiority  of at least  1 outcome  and non-inferiority  for both outcomes  are satisfied.  
 
g. Secondary  outcomes . Treatment  effects  on continuous  secondary  outcomes  which  are either  
approximately  normally  distributed  or can be transformed  to approximate  normality  will be 
analyzed  using  linear  mixed  effect  models  similar  to those  described  for IENF D and NQOL -DN. 
Generalized  linear  mixed models  with outcome  models  appropriate  to each  outcome  variable  will 
be applied  for ordered  categorical  outcomes  measured  at the scheduled  follow -up visits  and for 
continuous  outcomes  that cannot  be transformed  to achieve  approximate  normality.  The 
treatment  effect  on the rate of falls will be estimated  using  negative  binomial  regression.   
 
g. Evaluation  of the clinical  meaning  of IENFD  change.  A major  secondary  objective  of the 
TopCSPN  study  is to explore  the clinical  meaning  of change  in IENFD.  TOPIRAMATE  may 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  46 of 67 potentially  affect  NQOL -DN and other  clinical  endpoints  (e.g.,  balance,  fall risk) through  direct  
effects  that are independent  of neuropa thy progression  (IENFD),  or through  indirect  effects,  which  
are mediated  through  a pathway  that incorporates  effects  of the treatment  on neuropathy  
progression  based  on IENFD.  Using  this conceptual  framework,  mechanistic  information  will be 
obtained  from three types  of analyses:   
M1) Evaluation  of the profile  of treatment  effects  on the QOL -DN and other  clinical  endpoints  
in comparison  to the treatment  effect  on the IENFD,     
M2) Evaluation  of regression  coefficients  relating  changes  in the QOL -DN and other  clinical  
endpoints  to the IENFD  slope,  controlling  for treatment  assignment,  
M3) Evaluation  of the “proportion  of the treatment  effect  explained  by the IENFD”84 for the 
QOL -DN and other  clinical  endpoints.   
 
If the treatment  does  not affect  NQOL -DN or another clinical  endpoint,  the M1 and M2 analyses  
will provide  understanding  of the null effect  of the treatment.  The evaluation  of the profile  of 
treatment  effects  in M1 will be performed  by plotting  the estimated  treatment  effects  on each  
outcome  with their 95% confidence  intervals.  Treatment  effects  on continuous  and categorical  
variables  will be estimated  using  linear  or generalized  linear  mixed  models  analogous  to those  
described  in Aim 1; the treatment  effect  on the rate of falls will be analyzed  using  negative  binomial  
regression.  Concordant  effects  for IENFD  and a particular  clinical  endpoint  will suggest  possible  
mediation  of the treatment  effect  on the clinical  endpoint  through  IENFD,  whereas  discordant  
effects  will suggest  IENFD  did not play a major  role (i.e. was not clinically  relevant).  Bootstrap  
resampling  will be used  to provide  95% confidence  limits  for ratios  of treatment  effects  on IENFD  
vs. effects  on the clinical  endpoints.   
 
The treatment  effect  estimates  in the M1 analyses  represent  direct  comparisons  of 
randomized  groups,  and hence  are not subject  to confounding  due to the randomized  trial design.  
This is not the case  for the M2 and M3 analyses,  as confounding  factors  that jointly  influence  both 
the intermediate  variables  and the NQOL -DN or other  clinical  endpoints  will lead to biased  
estimates85.  Failure  to recognize  this issue  has led to confusion  in prior applications  of path 
analysis  for evaluation  of mediating  factors86. Thus,  we will seek  to identify  and control  for baseline  
and follow-up factors  that may potentially  influence  both IENFD  and NQOL -DN or other  clinical  
endpoints  in the M2 and M3 analyses.87   
 
The regression  coefficients  of the IENFD  slope  in the M2 analyses  will provide  information  
concerning  the clinical  interpretatio n of the IENFD  slope  by characterizing  the difference  in the 
96-week  change  in the NQOL -DN associated  with a given  difference  in the IENFD  slope.   These  
analyses  will be carried  out using  a joint mixed  effects  model  in which  the NQOL -DN will be 
assumed  to be related  to the underlying  random  IENFD  slopes.   We have  experience  fitting  similar  
joint models  using  the SAS procedure  NLMIXED88.  In the M3 analyses,  the proportion  of 
treatment  effect  explained  (PTE)  by the IENFD  slope  on the NQOL -DN will be obtained  by first 
estimating  the total effect  of the treatment  on change  in the NQOL -DN to 96 weeks  with 
adjustment  for potential  confounders  but not the IENFD  slope  using  a mixed  effects  model  as 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  47 of 67 described  in Aim 1, and then estimating  the treatment  effect  on the change  in the NQOL -DN that 
remains  after controlling  for the IENFD  slope  in a joint mixed  effects  model  which  adjusts  for the 
IENFD  slope  in addition  to the baseline  confounders.  The PTE by IENFD  will be estimated  by 
subtracting  the ratio of the adjusted  vs. unadjusted  treatment  effects  from 1, and a 95% 
confidence  interval  constructed  using  bootstrap  resampling.  Similar  analyses  will be used  to 
estimate  the regression  coefficients  of the IENFD  slope  (for the M2 analyses)  and the PTEs  
associated  with IENFD  (for the M3 analyses)  for other  clinical  endpoints.  To gain further  insight  
into the effects  of the topiramate  intervention  on different  components  of quality  of life, the M2 
and M3 analyses  will be repeated  for the five individual  subscales  of the NQOL -DN. 
 
10.1.  Outcomes  
10.1.1.  Primary  Outcome  (including  definition)  
IENFD  and the validated  NQOL -DN will serve  as co-primary  outcome  measures.  Rationale:  The 
choice  of endpoint  measures  is innovative,  and validation  of both measures  as potential  endpoints  
for use in a future Phase  III trial is a major  secondary  objective  of the current  proposal.  Most  
diabetic  neuropathy  trials  use nerve  conduction  studies  and clinical  examination  scales  [e.g. the 
Neuropathy  Impairment  Scale  Lower  Limb  (NIS-LL)] as primary  outcome  measures.   However,  
these  measures  are unresponsive  to change  in early  neuropathy66 and their patient -based  clinical  
meaning  has not been  established.   Current  criteria  for the minimal  clinically  important  difference  
in nerve  conduction  parameters  are based  on expe rt opinion  from nearly  25 years  ago67.  IENFD  
was selected  as an objective  measure  of axonal  integrity.   NQOL -DN was chosen  as a validated  
neuropathy  specific  measure  of patient  reported  function  and QOL.  
 
The Norfolk  Quality  of Life – Diabetic  Neuropathy  (NQOL -DN) scale:   IENFD  provides  an essential  
objective  biomarker  of axon  structure  but the patient  focused  clinical  meaning  of change  in IENFD  
has yet to be conclusively  determined.   Therefore,  incorporation  of a validated  measure  of patient  
symptoms  and function  is necessary.   Neuropathy  clinical  trials  should  assess  the impact  of 
therapy  on patient  function  and QOL.   Pain,  sensory  loss, imbalance,  falls and reduced  mobility  
combine  to reduce  QOL.   The NQOL -DN captures  the full spectrum  of DPN  related  symptoms.  
Data  from over 1000  structured  clinical  interviews  was reviewed  for content  validity  in an iterative  
multispecialty  process  in order  to develop  the instrument  27. 47 Items  inventory  DPN  symptoms  
and their impact  on function  and activities  of daily living.  The NQOL -DN accurately  distinguishes  
patients  with and without  DPN,  and correlates  significantly  with other  DPN  measures27. The 
NQOL -DN is responsive  to change.  In an 18-week  double  blind  crossover  trial of ruboxistaurin,  
topiramate  and placebo,  total NQOL -DN improved  significantly  with both topiramate  (12.2+/ -2.76)  
and ruboxistaurin  (-9.6+/ -4.1) but not placebo  (-5.6+/ - 3.5)24. Topiramate  reduces  pain,  and in a 
small  clinical  study  was associated  with increased  IENFD  over 18 weeks25, suggesting  an effect  
on small  axons.  By inhibiting  protein  kinas  C-beta,  Ruboxistaurin  is thought  to inhibit  
microvascular  injury.  Factor  analysis  has been  used  to group  NQOL -DN items  into 6 subscores:  
symptoms,  autonomic,  small  fiber,  large  fiber,  and activities  of daily living.  These  different  
subdomains  were  differentially  responsive  to ruboxistaurin  and topiramate.  Topiramate  treatment  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  48 of 67 was associated  with a significant  improvement  in the small  fiber and symptom  subscores,  which  
in turn significantly  correlated  with change  in IENFD24. By contrast,  ruboxistaurin  significantly  
improved  only the large  fiber subscore.  These  results  suggest  NQOL -DN subscores  are 
physiologically  valid measures  that reflect  different  peripheral  nerve  populations.   NQOL -DN will 
serve  as the co-primary  outcome  measure.    
 
Intraepidermal  nerve  fiber density:   Both CSPN  and early  diabetic  neuropathy  frequently  result  in 
loss of small  unmyelinated  axons  before  loss of larger  myelinated  fibers.   NCS  evaluate  
myelinated  axons,  but are not affected  by loss of small  lightly  myelinated  or unmyelinated  axons.   
While  unmyelinated  axons  may be particularly  vulnerable  to metabolic  stress,  they are also more  
plastic  than myelinated  fibers,  and have  more  robust  regenerative  capacity68.  Thus  a validated  
biomar ker of small  fiber integrity  would  be a preferred  endpoint  in a CSPN  clinical  trial.  IENFD  
directly  reflects  nociceptive  axons,  has demonstrated  reliability  equivalent  to nerve  conduction  
velocity69, and age and gender  specific  normative  data are availabl e52.  Epidermal  axons  are 
capable  of regeneration  in surgical  and chemical  axotomy  models70,71, and small  studies  suggest  
IENFD  improves  following  intervention  for diabetic  neuropathy11 and idiopathic   
neuropathy  in the setting  of prediabetes  10.  A small  open  label  trial of topiramate  in diabetic  
neuropathy  demonstrated  improved  IENFD  and microvascular  reactivity25 and a small  
randomized  trial of topiramate  versus  ruboxistuarin  or placebo  demonstrated  improvement  in 
IENFD  and the Total  Neuropathy  Score72 among  the topiramate  treated  participants24.   
 
10.1.2.  Secondary  Outcome(s)  
Secondary  outcome  measures  will include  measures  of neuropathy  symptoms  and signs,  function  
and mobility,  nerve  conduction  studies,  and metabolic  assessment.    
i. Neuropathy  symptoms:  
1.  NTSS653 
3.  Brief  Pain  Inventory  – Diabetic  Neuropathy  (BPI-DN) 54 
ii. Neuropathy  signs :   
  1.  Utah  Early  Neuropathy  Scale48 
 iii. Function  and mobility  
1.  6-minute  walk  test (6MWT)  56   
2.  Timed  up and Go (TUG)  58  
3.  ABC Scale .  
iv.Nerve  conduction  studies  including  Sural  sensory  amplitude  and distal  
latency/conduction  velocity,  and Peroneal  motor  amplitude,  distal  latency,  conduction  
velocity  between  the knee  and ankle  as described  above.  
v. Metabolic  assessment:  
• Height,  weight,  BMI, waist  circumfer ence  
• Fasting  glucose  and insulin  with calculation  of the “quantitative  insulin  
sensitivity  check  index”  (QUICKI)73 
• Hemoglobin  A1c 
• Fasting  lipid panel  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  49 of 67 10.1.3.  Exploratory  Outcomes  
Mechanistic  Studies:  This study  is not designed  to conclusively  elucidate  the precise  mechanisms  
underlying  topiramate’s  potential  efficacy  for CSPN  (weight  loss and resultant  metabolic  
improvement,  Na channel  inhibition),  but will include  biomarkers  specific  to these  putativ e 
mechanisms.  DNA  will be banked  from subjects  who agree  to the optional  DNA  sample  collection .  
Once  blind  has been  broken,  the genes  for voltage  gated  sodium  channels  of greatest  relevance  
to peripheral  nerve  function  (SCN2A,  3A, 4A, 8A, 9A and 10A)  will be sequenced  in subsets  of 
subjects  with the greatest  and least  clinical  improvement  in order  to examine  for sequence  
variants  associated  with topiramate  responsiveness.   The relationship  between  baseline  weight  
and metabolic  parameters,  and their improve ment,  and response  to therapy  will also be explored.   
Insulin  sensitivity  will be assessed  using  an indirect  surrogate  index  (e.g. the QUICKI)73. 
 
10.2.  Data  Monitoring  
All aspects  of the study  will be monitored  by qualified  individuals  designated  by the sponsor .  
Monitoring  will be conducted  according  to Good  Clinical  Practice  and applicable  government  
regulations.   The investigator  agrees  to allow  monitors  access  to the clinical  supplies,  dispensing  
and storage  areas,  and to the clinical  files of the study  subjects,  and, if requested,  agrees  to assist  
the monitors.  
 
Safety  monitoring  will include  careful  assessment  and appropriate  reporting  of adverse  events.   
Medical  monitoring  will include  contemporaneous  assessment  of serious  adverse  events.  
 
The monitoring  of subject  safety  and data quality  will follow  the NINDS  Guidelines  for Data  and 
Safety  Monitoring  in Clinical  Trials.   A Data  and Safety  Monitoring  Board  (DSMB)  appointed  by 
the NIH/NINDS  will meet  at 24-week  intervals  (or as determined  by the NINDS)  to review partially  
unblinded  study  data provided  by the study  statistician.   This committee  will monitor  rates  of 
adverse  events  and endpoints  in the trial and will monitor  the performance  of the trial. The 
frequency  and format  of DSMB  meetings,  reports,  and guidelines  for interim  analysis  will be 
agreed  upon  prior to study  subject  enrollment.  
 
The Protocol  PI will appoint  an Independent  Medical  Monitor  (IMM)  to review  all adverse  events,  
in a blinded  fashion,  on a periodic  basis.  In addition , the IMM will review all events  that meet  the 
regulatory  definition  of a Serious  Adverse  Event,  upon  receipt  of notification  via the Electronic  
Data  Capture  (EDC)  system.     
An adverse  event  (AE) is any unfavorable  and unintended  sign (including  a clinically  significant  
abnormal  laboratory  finding,  for example),  symptom,  or disease  temporally  associated  with a 
study,  use of a drug product  or device  whether  or not considered  related  to the drug product  or 
device.  The FDA,  Office  of Human  Research  Protection  (OHRP),  and NeuroN EXT CIRB  
requirements  for reporting  AEs will be followed.  Subjects  will be monitored  for AEs from the time 
they sign consent  until 30 days  following  permanent  discontinuation  of study  drug.  Adverse 
events during the screening phase (from the time the subje ct signs consent until they are randomized) 
shall only include events related to study procedures, i.e. infection of skin biopsy site.  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  50 of 67 At that point,  all ongoing  AEs will be followed  to resolution,  but no new AEs will be recorded.  The 
IMM/DSMB  will review  cumulative  AEs;  the frequency  of this review  will be determined  by the 
IMM/DSMB  in conjunction  with the Protocol  PI. 
 
Each  Clinical  Study  Site Investigator  and research  team  (co-Investigators,  research  nurse,  clinical  
trial coordinator)  are responsible  for identifying  and reporting  AEs and determining  the relationship  
of the event  to the study  drug/study  procedures.   Aggregate  reports  blinded  by treatment  group,  
detailed  by severity,  attribution  (expected  or unexpected),  and relationship  to the study  drug/s tudy 
procedures,  will be available  from the DCC  for review  by the IMM.  A separate  report  detailing  
protocol  compliance  will also be available  monthly  from the DCC  for review  by the Protocol  PI, 
who will provide  feedback  to individual  sites as needed.  The Protocol  Steering  Committee  (PSC)  
will advise  the Protocol  PI as to whether  the protocol  or informed  consent  document  requires  
revision  based  on these  reports.   
 
 
11. DATA  COLLECTION,  SITE  MONITORING,  AND  ADVERSE  EXPERIENCE  REPORTING  
11.1.  Data  Management  
Site person nel will collect,  transcribe,  correct,  and transmit  the data onto source  documents,  
CRFs,  and other  forms  used  to report,  track  and record  clinical  research  data.   The DCC  will 
monitor  clinical  sites to ensure  compliance  with data management  requirements  and Good  
Clinical  Practices.  The DCC  is responsible  for developing,  testing,  and managing  clinical  data 
management  activities,  as required,  at the study  sites,  the CCC,  and at the DCC.  
 
The general  NINDS  Common  Data  Elements  (CDE)  will be used  to construct  data collection  
forms.  All study  data will be collected  via systems  created  in collaboration  with the DCC  and will 
comply  with all applicable  guidelines  regarding  patient  confidentiality  and data integrity.  
 
11.1.1.  Registration  
Registration  of subjects  on this protocol  will employ  an interactive  data system  in which  the clinical  
study  site will attest  to the subject’s  eligibility  as per protocol  criteria  and obtain  appropriate  
informed  consent.  NeuroNEXT  CIRB  approval  for the protocol  must  be on file at the DCC  before 
accrual  can occur  from the clinical  study  site. 
 
The DCC  will use a system  of coded  identifiers  to protect  subject  confidentiality.   When  the subject  
is registered  to participate  in the study  using  the DCC -provided  web-based  registration,  the 
system  will assign  a subject  ID number.  The unique  ID code  will include  a protocol  ID, a site ID, 
and a unique  subject  ID.  To confirm  the correct  subject  ID, the data entry  system  will require  a 
second  entry  of the unique  subject  ID and compare  for consistency.   In this fashion,  no personal  
identifiers  would  be accessible  to the DCC  and the data will be collected  on the correctly  identified  
subject.   
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  51 of 67 11.1.2.  Data  Entry  
Data  entry  will occur  at the enrolling  clinical  study  sites.  Data  quality  assurance  and analyses  will 
be performed  by the DCC.   The DCC,  located  at the University  of Iowa,  will coordinate  all data 
and statistical  services  for the study,  as well as on-site monitoring  for all participating  clinical  study  
sites.  
 
Data  collection  for this study  will be accomplished  with online  electronic  case  report  forms.   Using  
encrypted  communication  links,  online  forms  will be developed  that contain  the requisite  data 
fields.    
 
11.2.  Role  of Data  Management  
Data  Management  (DM)  is the development,  execution  and supervision  of plans,  policies,  
programs,  and practices  that control,  protect,  deliver,  and enhance  the value  of data and 
information  assets.  
 
All data will be managed  in compliance  with NeuroNEXT  policies,  and applicable  Spons or and 
regulatory  requirements.  The DCC  will instruct  site personnel  to collect,  transcribe,  correct,  and 
transmit  the data onto source  documents,  CRFs,  and other  forms  used  to report,  track  and record  
clinical  research  data.   The DCC  will monitor  clinical  sites to ensure  compliance  with data 
management  requirements  and Good  Clinical  Practices.  The DCC  is responsible  for developing,  
testing,  and managing  clinical  data management  activities,  as required,  at the clinical  study  sites 
(CSS),  the CCC,  and at the DCC.  
 
The DCC  is responsible  for all aspects  of clinical  data management,  and for properly  instructing  
key study  personnel  (including  the CCC,  the CSS,  and DCC  staff)  on how to collect,  transcribe,  
correct  and transmit  the data onto CRFs  or other  data collection  forms  and logs.  
 
The DCC  is responsible  for establishing  procedures  to ensure  that clinical  data management  
activities  occur  as required  at the CCC,  the CSS,  and at the DCC.  
11.3.  Quality  Assurance  
By signing  this protocol,  the Sponsor  and Investigator  agree  to be responsible  for implementing  
and maintaining  quality  control  and quality  assurance  systems  with written  standard  operating  
procedures  (SOPs)  to ensure  that studies  are conducted  and data are generated,  documented,  
and reported  in compliance  with the protocol,  accepted  standards  of GCP,  and all applicable  
federal,  state,  and local laws,  rules  and regulations  relating  to the conduct  of the clinical  study.  
11.3.1.  Development  of Monitoring  Plan  
Onsite  monitoring  visits  will be conducted  by DCC  monitors  according  to a pre-defined  Monitoring  
Plan.   The monitoring  plan will detail  the frequency  of on-site visits,  the study  data to be monitored,  
the review  of any regulatory  files, drug and supplies  accounta bility (if applicable),  documentation  
of the on-site visit, and the resolution  process  for data errors  that are discovered  during  the visits.    
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  52 of 67 All participating  clinical  study  sites will be monitored  at least  once  after a study  initiation  visit and 
all sites will have  a close -out visit for each  protocol.   One on-site monitoring  visit is anticipated  for 
each  clinical  study  site per year.   All subjects  will be monitored  for inclusion  and exclusion  criteria,  
informed  consent  procedures,  and adverse  events.   A certain  percentage  of data is also 
monitored/  source  data verified  against  the data entered  into the study  database.   The monitoring  
plan will include  flexibility  to revise  the frequency  of visits  or data monitored  depending  on clinical  
study  site or study related  issues.  
11.3.2.  Site Monitoring  Visits  
On-site monitoring  visits  will be conducted  by DCC  monitors  according  to a pre-defined  monitoring  
plan for each  protocol.   The goal of on-site monitoring  is to analyze  (review)  the data as it is 
collected,  to check  the validity  and integrity  of the data,  to verify  source  documentation,  to ensure  
protection  of human  subjects,  and to ensure  protocol  compliance  with federal  regulations.   During  
the monitoring  visit, the monitor  assesses  the overall  status  of the study,  staff,  and facilities  to 
determine  whether  the study  is being  conducted  per protocol  and in compliance  with regulatory  
requirements.   The monitor  also conducts  a CRF review  that includes  checks  of all adverse  event  
documentation,  verifies  the presence  of all critical  correspondence  and records  related  to 
investigational  products  and clinical  supplies  (if applicable),  and determines  if protocol  violations  
have  occurred  and are documented  properly.   After  the monitoring  visit, the monitor  documents  
the result s of the monitoring  visit and completes  a post-visit monitoring  letter  that conveys  any 
issues  discovered  during  the visit and the need  for data corrections,  if appropriate.   Drug  and 
supplies  accountability  may also be monitored  during  the site visit.  The DCC  will work  closely  
with the CCC  to monitor  and document  drug distribution  from the manufacturers  to the clinical  
study  sites (CSS).   Each  CSS will be provided  with a drug accountability  log which  will be reviewed  
by the DCC  monitors  and reconciled  with distribution  logs.  At the study  closeout  visit, the monitors  
confirm  that appropriate  data have  been  reviewed,  source  documentation  has been  verified,  and 
all required  documents  are present  in the Study  Regulatory  File. 
11.3.3.  Laboratory  Data  Flow  
Safety  Monito ring Labs : The DCC  will provide  laboratories  with online  forms  and/or  electronic  
data exchange  mechanisms  - depending  on their capabilities  and needs  - to enter,  update  and 
obtain  relevant  data.  When  a blood  or urine  sample  has been  obtained,  the clinical  study  site 
study  coordinator  will send  the sample  (subject  ID, site ID, and protocol  ID numbers  will be used)  
to the University  of Rochester  central  laboratory.  Results  will be sent via a secure  system  to 
University  of Rochester  laboratory  with no individu al-identifying  information  on the report.  The 
laboratory  will electronically  communicate  the test results  to the respective  clinical  study  sites in 
a secure  manner.   The laboratory  will also transfer  test results  electronically  to the DCC.  
 
11.4.  Adverse  Experie nce Reporting  
The adverse  event  (AE) definitions  and reporting  procedures  provided  in this protocol  comply  with 
all applicable  United  States  Food  and Drug  Administration  (FDA)  regulations  and International  
Conference  on Harmonization  (ICH)  guidelines.   The Site Investigator  will carefully  monitor  each  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  53 of 67 subject  throughout  the study  for possible  adverse  events.   All AEs will be documented  on CRFs  
designed  specifically  for this purpose.   It is important  to report  all AEs,  especially  those  that result  
in permane nt discontinuation  of the investigational  product  being  studied,  whether  serious  or non-
serious.  
Each  clinical  study  site’s  Principal  Investigator  and research  team  are responsible  for identifying  
adverse  events  and reporting  them  through  the DCC  Online  Adverse  Event  Reporting  System.   
Investigators  are also responsible  for complying  with NeuroNEXT  CIRB’s  reporting  requirements  
for all safety  reports.   Copies  of each  report  and documentation  of IRB notification  and receipt  will 
be kept in the investigator’s  study  file.  
 
An adverse  event  is defined  as: “…an  unfavorable  and unintended  sign,  symptom,  or disease  
associated  with a subject’s  participation  in this research  trial.”  
 
Serious  adverse  events  include  those  events  that: “result  in death;  are life-threatening;  require  
inpatient  hospitalization  or prolongation  of existing  hospitalization;  create  persistent  or significant  
disability/incapacity,  or a congenital  anomaly/birth  defects.”   
 
Unexpected  adverse  event  is defined  as any adverse  experience…the  specificity  or severity  of 
which  is not consistent  with the risks described  in the protocol.   
 
Expected  adverse  events  are those  that are known  to be associated  with or have  the potential  to 
arise  as a consequence  of participation  in the study.  
 
On-line Adverse  Event  Reporting  System   
Upon  entry  of a serious  adverse  event  by a site investigator,  the DCC  Online Adverse  Event  
Reporting  System  will immediately  notify  the Independent  Medical  Monitor  (IMM).    
 
Within  24 hours  (of learning  of the event),  investigators  must  report  any Serious  Adverse  Event  
(SAE)  Investigators  must  report  all other  AEs within  5 work ing days/7  calendar  days  (of learning  
of the event).  
 
Serious  adverse  events : The site investigator  determines  causality  (definitely  not related,  probably  
not related,  possibly  related,  probably  related,  definitely  related)  of the adverse  event.  The IMM 
will review  the SAE report.   The IMM may request  further  information  if necess ary.  The Online  
Adverse  Event  Reporting  System  maintains  audit  trails  and stores  data (and data updated)  and 
communication  related  to any adverse  event  in the study.  The IMM may determine  that the 
Serious  Adverse  Event  requires  expedited  reporting  to the FDA.   The DCC  will prepare  a 
Medwatch  safety  report  for submission  to the FDA.   If warranted,  the IMM will notify  the DSMB  
chair.   The DSMB  may suggest  changes  to the protocol  or consent  form to the Study  Chair  as a 
consequence  of adverse  events.   
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  54 of 67 Non-serious adverse  events : Non-serious  adverse  events  that are reported  to or observed  by the 
investigator  or a member  of his research  team  will be submitted  to the DCC  in a timely  fashion  
(within  5 working  days).  The events  will be presented  in tabular  form and given  to the IMM on a 
quarterly  basis  or as requested.  Local  site investigators  are also required  to fulfill all reporting  
requirements  of their local institutions.  
 
The DCC  will prepare  aggregate  reports  of all adverse  events  (serious/not  serious,  
expect ed/unexpected  and relationship  to study  drug)  for the IMM and the DSMB  on a quarterly  
basis  or as requested.  In addition,  all adverse  events  will be coded  using  the MedDRA  system.  A 
separate  report  detailing  protocol  compliance  will also be available  from the DCC  for DSMB  and/or  
site review  monthly  or as requested.  The research  team  will then evaluate  whether  the protocol  
or informed  consent  document  requires  revision  based  on the reports.   
11.4.1.  Definitions  of Adverse  Events,  Suspected  Adverse  Drug  Reactions  & Serious  
Adverse  Events  
11.4.1.1.  Adverse  Event  Collection  and Reporting  
 
Subjects  will be monitored  for AEs from the time they sign consent  until 30 days  following  
permanent  discontinuation  of study  drug.  Adverse events during the screening phase (from the 
time the s ubject signs consent until they are randomized) shall only include events related to 
study procedures, i.e. infection of skin biopsy site.    If not related to study procedures, any new 
or worsened medical conditions reported during the screening process will be recorded in  
medical  history.  
An adverse  event  (AE) is any unfavorable  and unintended  sign (including  a clinically  significant  
abnormal  laboratory  finding,  for example),  symptom,  or disease  temporally  associated  with a 
study,  use of a drug product  or device  whether  or not considered  related  to the drug product  or 
device.   
 
Adverse  drug reactions  (ADR)  are all noxious  and unintended  responses  to a medicinal  product  
related  to any dose.   The phrase  “responses  to a medicinal  product”  means  that a causa l 
relationship  between  a medicinal  product  and an adverse  event  is at least  a reasonable  possibility,  
i.e., the relationship  cannot  be ruled  out.  Therefore,  a subset  of AEs can be classified  as 
suspected  ADRs,  if there  is a causal  relationship  to the medi cinal product.  
 
Examples  of adverse  events  include:  new conditions,  worsening  of pre-existing  conditions,  
clinically  significant  abnormal  physical  examination  signs  (i.e. skin rash,  peripheral  edema,  etc), 
or clinically  significant  abnormal  test results  (i.e. lab values  or vital signs),  with the exception  of 
outcome  measure  results,  which  are not being  recorded  as adverse  events  in this trial (they  are 
being  collected,  but analyzed  separately).   
 
Stable  chronic  conditions  (i.e., diabetes,  arthritis)  that are present  prior to the start of the study  
and do not worsen  during  the trial are NOT  considered  adverse  events.  Chronic  conditions  that 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  55 of 67 occur  more  frequently  (for intermittent  conditions)  or with greater  severity,  would  be considered  
as worsened  and therefore  would  be recorded  as adverse  events.  
 
Adverse  events  are generally  detected  in two ways:  
  
Clinical  → symptoms  reported  by the subject  or signs  detected  on examination.  
 
Ancillary  Tests  → abnormalities  of vital signs,  laboratory  tests,  and other  diagnostic  procedures  
(other  than the outcome  measures:  the results  of which  are not being  captured  as AEs).  
 
If discernible  at the time of completing  the AE log, a specific  disease  or syndrome  rather  than 
individual  associated  signs  and symptoms  should  be identified  by the Site Investigator  and 
recorded  on the AE log.  However,  if an observed  or reported  sign,  symptom,  or clinically  
significant  laboratory  anomaly  is not considered  by the Site Investigator  to be a component  of a 
specific  disease  or syndrome,  then it should  be recorded  as a separate  AE on the AE log.  
Clinically  significant  laboratory  abnormalities,  such  as those  that require  intervention,  are those  
that are identified  as such  by the Site Investigator.  
 
An unexpected  adverse  event  is any adverse  event,  the specificity  or severity  of which  is not 
consistent  with the current  Investigators  Brochure  or package  insert  or described  in the protocol.   
An unexpected,  suspected  adverse  drug reaction  is any unexpected  adverse  event  that, in the 
opinion  of the Site Investigator  or Sponsor,  there  is a reasonable  possibility  that the investigational  
product  caused  the event.  
 
11.4.1.2.   Serious  Adverse  Events  
A serious  adverse  event  (SAE)  is defined  as an adverse  event  that meets  any of the following  
criteria:  
1. Results  in death.  
2. Is life threatening:  that is, poses  an immediate  risk of death  as the event  occurred.  
a. This serious  criterion  applies  if the study  subject,  in the view of the Site Investigator  or 
Sponsor,  is at immediate  risk of death  from the AE as it occurs .  It does not apply  if an 
AE hypothetically  might  have  caused  death  if it were  more  severe.  
3. Requires  inpatient  hospitalization  or prolongation  of existing  hospitalization.  
a. Hospitalization  for an elective  procedure  (including  elective  PEG  tube/g -tube/feeding  
tube placement)  or a routinely  scheduled  treatment  is not an SAE by this criterion  
because  an elective  or scheduled  “procedure ” or a “treatment”  is not an untoward  
medical  occurrence.  
4. Results  in persistent  or significant  disability  or incapacity.  
a. This serious  criterion  applies  if the “disability”  caused  by the reported  AE results  in a 
substantial  disruption  of the subject’s  ability  to carry  out normal  life functions.  
5. Results  in congenital  anomaly  or birth defect  in the offspring  of the subject  (whether  the 
subject is male  or female).    
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  56 of 67 6. Necessitates  medical  or surgical  intervention  to preclude  permanent  impairment  of a body  
function  or permanent  damage  to a body  structure.  
7. Important  medical  events  that may not result  in death,  are not life-threatening,  or do not 
require  hospitalization  may also be considered  SAEs  when,  based  upon  appropriate  medical  
judgment,  may jeopardize  the subject  and may require  medical  or surgical  intervention  to 
prevent  one of the outcomes  listed  in this definition.   Examples  of such  medic al events  include  
blood  dyscrasias  or convulsions  that do not result  in inpatient  hospitalization,  or the 
development  of drug dependency  or drug abuse.  
 
An inpatient  hospital  admission  in the absence  of a precipitating,  treatment -emergent,  clinical  
adverse  event  may meet  criteria  for "seriousness"  but is not an adverse  experience,  and will 
therefore,  not be considered  an SAE.   An example  of this would  include  a social  admission  
(subject  admitted  for other  reasons  than medical,  e.g., lives far from the hospi tal, has no place  to 
sleep).  
 
A serious,  suspected  adverse  drug reaction  is an SAE that, in the opinion  of the Site Investigator  
or Sponsor,  suggests  a reasonable  possibility  that the investigational  product  caused  the event.  
 
The Site Investigator  is responsible  for classifying  adverse  events  as serious  or non-serious.  
 
11.4.2.  Assessment  and Recording  of Adverse  Events  
This study  will utilize  the CTCAE  version  4.0 coding  system  for adverse  event  recording.   Adverse  
events  reported  using  CTCAE  will be recoded  into MedDRA  terms  by the DCC.  
 
Assessment  of Adverse  Events  
At each  visit (including  telephone  interviews),  the subject  will be asked  “Have  you had any 
problems  or symptoms  since  your last visit?”  in order  to determine  the occurrence  of adverse  
events.  If the subject  reports  an adverse  event,  the Investigator  will determine:  
 
1. Type  of event  
2. Date  of onset  and resolution  (duration)  
3. Severity  (mild,  moderate,  severe)  
4. Seriousness  (does  the event  meet  the above  definition  for an SAE)  
5. Causality,  relation  to investigational  product  and disease  
6. Action  taken  regarding  investigational  product  
7. Outcome  
 
Relatedness  of Adverse  Event  to Investigational  Product  
The relationship  of the AE to the investigational  product  should  be specified  by the Site 
Investigator,  using the following  definitions:  
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  57 of 67 1. Not Related:  Concomitant  illness,  accident  or event  with no reasonable  association  with 
treatment.  
2. Unlikely:  The reaction  has little or no temporal  sequence  from administration  of the 
investigational  product,  and/or  a more  likely alternative  etiology  exists.  
3. Possibly  Related:  The reaction  follows  a reasonably  temporal  sequence  from administration  of 
the investigational  product  and follows  a known  response  pattern  to the suspected  
investigational  product;  the reaction  could  have  been  produced  by the investigational  product  
or could  have  been  produced  by the subject’s  clinical  state  or by other  modes  of therapy  
administered  to the subject.  (suspected  ADR)  
4. Probably  Related:  The reaction  follows  a reasonably  temporal  sequence  from administration  
of investigational  product;  is confirmed  by discontinuation  of the investigational  product  or by 
re-challenge;  and cannot  be reasonably  explained  by the known  characteristics  of the subject’s  
clinical  state.  (suspected  ADR)  
5. Definitely  Related : The reaction  follows  a reasonable  temporal  sequence  from administration  
of investigational  product;  that follows  a known  or expected  response  pattern  to the 
investigational  product;  and that is confirmed  by improvement  on stopping  or reducing  the 
dosage  of the investigational  product,  and reappearance  of the reaction  on repeated  exposure.  
(suspected  ADR)  
 
Recording  of Adverse  Events  
All clinical  adverse  events  are recorded  in the Adverse  Event  (AE) Log in the subject’s  study  
binder.  The site should  fill out the AE Log and enter  the AE information  into the online  Adverse  
Event  Reporting  System  within  5 working  days  of the site learning  of a new AE or receiving  an 
update  on an existing  AE.   
 
Please  Note:  Serious  Adverse  Events  (SAEs)  must  be reported  to the NeuroNEXT  Data  
Coordinating  Center  within  24 hours  of the site learning  of the SAE.   
 
Entries  on the AE Log (and into the online  Adverse  Event  Reporting  System)  will include  the 
following:  name  and severity  of the event,  the date of onset,  the date of resolution,  relationship  to 
investigational  product,  action  taken,  and primary  outcome  of event.  
 
Adverse  Events  and Serious  Adverse  Events  - Reportable  Events  
The following  are considered  reportable  events  and must  be reported  to the NeuroNEXT  Data  
Coordi nating  Center  within  24 hours  of the site being  notified  of the event.   
 
• All events  that meet  the above  criteria  for Serious  Adverse  Events  (SAEs)  
 
All occurrences  of Serious  Adverse  Events  (SAEs)  must  be reported  within  24 hours  of discovery  
of the event.    All other  Adverse  Events  (AEs)  must  be reported  within  5 business  days/7  calendar  
days  (of discovery  of the event).  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  58 of 67  
Adverse  Event  Data  Management  System  (AEDAMS)  
Upon  entry  of a serious  adverse  event  by a clinical  site, the DCC  Online  Adverse  Event  Reporting  
System  will immediately  notify  the IMM.  If warranted,  the IMM will notify  the DSMB  chair.   
 
Serious  adverse  events : The site investigator  determines  causality  (definitely  not related,  probably  
not related,  possibly  related,  probably  related,  definit ely related)  of the adverse  event.  The IMM 
will review  the SAE report.   The IMM may request  further  information  if necessary.   The DSMB  
may suggest  changes  to the protocol  or consent  form to the Project  PI as a consequence  of 
adverse  events.  The Online  Adverse Event  Reporting  System  maintains  audit  trails  and stores  
data (and data updated)  and communication  related  to any adverse  event  in the study.   
 
Non-serious  adverse  events : Non-serious  adverse  events  that are reported  to or observed  by the 
investigator  or a member  of his research  team  will be submitted  to the DCC  within  5 working  days.  
The events  will be presented  in tabular  form and given  to the IMM on a quarterly  basis  or as 
requested.  Local  site investigators  are also required  to fulfill all reporting  requirements  of their 
local institutions.  
 
The DCC  will prepare  aggregate  reports  of all adverse  events  (serious/not  serious  and expected,  
unexpected)  for the DSMB.   
 
12. HUMAN  SUBJECTS  
Documented  approval  from the NeuroNEXT  CIRB  will be obtained  for all participating  centers  
prior to clinical  trial start,  according  to ICH GCP,  local laws,  regulations  and organization.  When  
necessary,  an extension,  amendment  or renewal  of the CIRB  approval  must  be obtained.  
Evidence  of training  in responsible  conduct  of research  shall be on file for each  CSS PI and co-
investigator.  
12.1.  Institutional  Review  Board  (IRB)  Review  and Informed  Consent  
This protocol  and the informed  consent  document  (Appendix  A) and any subsequent  
modifications  will be reviewed  and approved  by the NeuroNEXT  CIRB  responsible  for oversight  
of the study.   A signed  consent  form,  approved  by the NeuroNEXT  CIRB,  will be obtain ed from 
the subject.    The consent  form will describe  the purpose  of the study,  the procedures  to be 
followed,  and the risks and benefits  of participation.   A copy  of the consent  form will be given  to 
the subject  and this fact will be documented  in the subject’s record.  
12.2.  Subject  Confidentiality  
All laboratory  specimens,  evaluation  forms,  reports,  video  recordings,  and other  records  that leave  
the clinical  study  site will be identified  only by the study  specific  Subject  Identification  Number  
(SID)  to maintain  subject  confidentiality.   All records  will be kept in a locked  file cabinet.   All 
computer  entry  and networking  programs  will be done  using  study  specific  SIDs  only.   Clinical  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  59 of 67 information  will not be released  without  written  permission  of the subject,  except as necessary  for 
monitoring  by CIRB,  the FDA,  the NINDS,  the OHRP,  the sponsor,  or the sponsor’s  designee.  
 
12.3.  Study  Modification/Discontinuation  
The study  may be modified  or discontinued  at any time by the CIRB,  the NINDS,  the sponsor,  the 
OHRP,  the FDA,  or other  government  agencies  as part of their duties  to ensure  that research  
subjects  are protected.  
13. PUBLICATION  OF RESEARCH  FINDINGS  
Publication  of the results  of this trial will be governed  by the policies  of the NeuroNEXT  Network  
and procedures  developed  by the NeuroNEXT  Data  Sharing  and Publication  Committee.   Any 
presentation,  abstract,  or manuscript  will be made  available  for review  by the sponsor  and the 
NINDS  prior to submission.  
 
14. REFERENCES  
1. Gregg  EW, Sorlie  P, Paulose -Ram  R, Gu Q, Eberha rdt MS, Wolz  M, et al. Prevalence  
of lower -extremity  disease  in the US adult  population  >=40  years  of age with and 
without  diabetes:  1999 -2000  national  health  and nutrition  examination  survey.  
Diabetes  Care.  2004  Jul;27(7):1591 –7.  
2. Smith  AG. Impaired  glucose  tolerance  and metabolic  syndrome  in idiopathic  
neuropathy.  Journal  of the Peripheral  nervous  system : JPNS.  2012  May;17  Suppl  
2:15–21.  
3. Smith  AG, Singleton  JR. The diagnostic  yield of a standardized  approach  to idiopathic  
sensory -predominant  neurop athy.  Arch.  Intern.  Med.  2004  May 10;164(9):1021 –5.  
4. Singleton  JR, Smith  AG, Bromberg  MB. Painful  sensory  polyneuropathy  associated  
with impaired  glucose  tolerance.  Muscle  Nerve.  2001;  24:1225 –8.  
5. Ziegler  D, Rathmann  W, Dickhaus  T, Meisinger  C, Mielc k A, KORA  Study  Group.  
Neuropathic  pain in diabetes,  prediabetes  and normal  glucose  tolerance:  the 
MONICA/KORA  Augsburg  Surveys  S2 and S3. Pain Med.  2009  ed. Blackwell  
Publishing  Inc; 2009  Mar;10(2):393 –400.  
6. Smith  AG, Singleton  JR. Obesity  and hyperlip idemia  are risk factors  for early  diabetic  
neuropathy.  Journal  of Diabetes  and Its Complications.  2013  May 31. PMCID:  
PMC3766404  
7. Vincent  AM, Hinder  LM, Pop-Busui  R, Feldman  EL. Hyperlipidemia:  a new 
therapeutic  target  for diabetic  neuropathy.  Journal  of the Peripheral  nervous  system : 
JPNS.  2009  ed. 2009  Dec;14(4):257 –67.  
8. Davidson  EP, Coppey  LJ, Calcutt  NA, Oltman  CL, Yorek  MA. Diet-induced  obesity  in 
Sprague -Dawley  rats causes  microvascular  and neural  dysfunction.  Diabetes  Metab  
Res Rev. 2010  ed. John  Wiley  & Sons,  Ltd; 2010  May;26(4):306 –18. PMCID:  
PMC2878284  
9. Obrosova  IG, Ilnytska  O, Lyzogubov  VV, Pavlov  IA, Mashtalir  N, Nadler  JL, et al. 
High-fat diet induced  neuropathy  of pre-diabetes  and obesity:  effects  of “healthy”  diet 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  60 of 67 and aldose  reductas e inhibition.  Diabetes.  2007  ed. 2007  Oct;56(10):2598 –608.  
10. Smith  AG, Russell  J, Feldman  EL, Goldstein  J, Peltier  A, Smith  S, et al. Lifestyle  
intervention  for pre-diabetic  neuropathy.  Diabetes  Care.  2006  Jun;29(6):1294 –9.  
11. Kludig  P, Pasnoor  M, Singh R, Jernigan  S, Farmer  K, Rucker  J, et al. The Effect  of 
Exercise  on Neuropathic  Symptoms,  Nerve  Function,  and Cutaneous  Innervation  in 
 People  with Diabetic  Peripheral  Neuropathy.  Journal  of Diabetes  and Its 
Complications.  2013  (26):424 –9.  
12. Singleto n JR, Marcus  RL, Jackson  JE, K Lessard  M, Graham  TE, Smith  AG. Exercise  
increases  cutaneous  nerve  density  in diabetic  patients  without  neuropathy.  Ann Clin 
Transl  Neurol.  2014  Oct;1(10):844 –9. PMCID:  PMC4241811  
13. Singleton  JR, Marcus  RL, Lessard  MK, Jackson JE, Smith  AG. Supervised  exercise  
improves  cutaneous  reinnervation  capacity  in metabolic  syndrome  patients.  Ann. 
Neurol.  2014  Nov 12; n/a–n/a. PMCID:  PMC4293306  
14. Huang  J, Han C, Estacion  M, Vasylyev  D, Hoeijmakers  JGJ, Gerrits  MM, et al. Gain -
of-function  mutations  in sodium  channel  Na(v)1.9  in painful  neuropathy.  Brain.  2014  
Jun;137(Pt  6):1627 –42.  
15. Argyriou  AA, Cavaletti  G, Antonacopoulou  A, Genazzani  AA, Briani  C, Bruna  J, et al. 
Voltage -gated  sodium  channel  polymorphisms  play a pivotal  role in the development  
of oxaliplatin -induced  peripheral  neurotoxicity:  results  from a prospective  multicenter  
study.  Cancer.  2013  Oct;119(19):3570 –7.  
16. Channelopathies,  painful  neuropathy,  and diabetes:  which  way does  the causal  
arrow  point?  2014  Oct;20(10):5 44–50.  
17. Faber  CG, Hoeijmakers  JG, Ahn HS, Cheng  X, Han C, Choi JS, et al. Gain  of function  
Na(V)  1.7 mutations  in idiopathic  small  fiber neuropathy.  Ann. Neurol.  2011  ed. 2011  
May 20;71(1):26 –39.  
18. Bennett  DLH.  Voltage -gated  sodium  channel  mutations  and painful  neuropathy:  
Na(v)1.9  joins the family.  Brain.  2014  Jun;137(Pt  6):1574 –6.  
19. Coomans  CP, Geerling  JJ, van den Berg  SAA,  van Diepen  HC, Garcia -Tardon  N, 
Thomas  A, et al. The insulin  sensitizing  effect  of topiramate  involves  KATP  channel  
activa tion in the central  nervous  system.  Br J Pharmacol.  2013  Oct;170(4):908 –18. 
PMCID:  PMC3799603  
20. El-Abhar  HS, Schaalan  MF. Topiramate -induced  modulation  of hepatic  molecular  
mechanisms:  an aspect  for its anti-insulin  resistant  effect.  Pereira  RI, editor.  PLoS  
ONE.  2012;7(5):e37757.  PMCID:  PMC3359316  
21. Kramer  CK, Leitao  CB, Pinto  LC, Canani  LH, Azevedo  MJ, Gross  JL. Efficacy  and 
safety  of topiramate  on weight  loss: a meta -analysis  of randomized  controlled  trials.  
Obes  Rev. 2011  May;12(5):e338 –47.  
22. Raskin P, Donofrio  PD, Rosenthal  NR, Hewitt  DJ, Jordan  DM, Xiang  J, et al. 
Topiramate  vs placebo  in painful  diabetic  neuropathy:  analgesic  and metabolic  
effects.  Neurology.  2004  Sep 14;63(5):865 –73.  
23. Donofrio  PD, Raskin  P, Rosenthal  NR, Hewitt  DJ, Jordan  DM, Xiang  J, et al. Safety  
and effectiveness  of topiramate  for the management  of painful  diabetic  peripheral  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  61 of 67 neuropathy  in an open -label  extension  study.  Clin Ther.  2005  Sep;27(9):1420 –31.  
24. Boyd  A, Casselini  C, Vinik  E, Vinik  A. Quality  of life and objective  measures  of 
diabetic  neuropathy  in a prospective  placebo -controlled  trial of ruboxistaurin  and 
topiramate.  J Diabetes  Sci Technol.  2011  May;5(3):714 –22. PMCID:  PMC3192638  
25. Boyd  AL, Barlow  PM, Pittenger  GL, Simmons  KF, Vinik  AI. Topiramate  improve s 
neurovascular  function,  epidermal  nerve  fiber morphology,  and metabolism  in 
patients  with type 2 diabetes  mellitus.  Diabetes  Metab  Syndr  Obes.  2010;  3:431 –7. 
PMCID:  PMC3047986  
26. Lopes  LS, Pereira  SS, Silva  LL, Figueiredo  KA, Moura  BA, Almeida  FRC,  et al. 
Antinociceptive  effect  of topiramate  in models  of acute  pain and diabetic  neuropathy  
in rodents.  Life Sci. 2009  Jan 16;84(3 -4):105 –10.  
27. Vinik  EJ, Hayes  RP, Oglesby  A, Bastyr  E, Barlow  P, Ford-Molvik  SL, et al. The 
development  and validation  of the Norfolk  QOL -DN, a new measure  of patients'  
perception  of the effects  of diabetes  and diabetic  neuropathy.  Diabetes  Technol.  
Ther.  2005  Jun;7(3):497 –508.  
28. Vinik  EJ, Paulson  JF, Ford-Molvik  SL, Vinik  AI. German -translated  Norfolk  quality  of 
life (QOL -DN) identifies  the same  factors  as the English  version  of the tool and 
discriminates  different  levels  of neuropathy  severity.  J Diabetes  Sci Technol.  2008  
Nov;2(6):1075 –86. PMCID:  PMC2769831  
29. Ben-Menachem  E, Axelsen  M, Johanson  EH, Stagge  A, Smith  U. Predic tors of weight  
loss in adults  with topiramate -treated  epilepsy.  Obes.  Res. 2003  Apr;11(4):556 –62.  
30. Caricilli  AM, Penteado  E, de Abreu  LL, Quaresma  PGF,  Santos  AC, Guadagnini  D, 
et al. Topiramate  treatment  improves  hypothalamic  insulin  and leptin  signal ing and 
action  and reduces  obesity  in mice.  Endocrinology.  2012  Sep;153(9):4401 –11.  
31. Abo-Elmatty  DM, Zaitone  SA. Topiramate  induces  weight  loss and improves  insulin  
sensitivity  in dietary  obese  rats: comparison  to sibutramine.  Eur Rev Med Pharmacol  
Sci. 2011  Oct;15(10):1187 –95.  
32. Liang  Y, Chen  X, Osborne  M, DeCarlo  SO, Jetton  TL, Demarest  K. Topiramate  
ameliorates  hyperglycaemia  and improves  glucose -stimulated  insulin  release  in ZDF 
rats and db/db  mice.  Diabetes  Obes  Metab.  2005  Jul;7(4):360 –9.  
33. Gaede  P, Vedel  P, Larsen  N, Jensen  GV, Parving  HH, Pedersen  O. Multifactorial  
intervention  and cardiovascular  disease  in patients  with type 2 diabetes.  N. Engl.  J. 
Med.  2003rd  ed. 2003  Jan 30;348(5):383 –93.  
34. Chong  MS, Libretto  SE. The rationale  and use of topiramate  for treating  neuropathic  
pain.  Clin J Pain.  2003  Jan;19(1):59 –68.  
35. Raskin  J, Pritchett  YL, Wang  F, D'Souza  DN, Waninger  AL, Iyengar  S, et al. A double -
blind,  randomized  multicenter  trial comparing  duloxetine  with placebo  in the 
managemen t of diabetic  peripheral  neuropathic  pain.  Pain Med.  2005  Sep-
Oct;6(5):346 –56.  
36. Zhang  J-L, Yang  J-P, Zhang  J-R, Li R-Q, Wang  J, Jan J-J, et al. Gabapentin  reduces  
allodynia  and hyperalgesia  in painful  diabetic  neuropathy  rats by decreasing  
expression  level of Nav1.7  and p-ERK1/2  in DRG  neurons.  Brain  Res. 2013  Feb 1; 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  62 of 67 1493:13 –8.  
37. Argyriou  AA, Bruna  J, Marmiroli  P, Cavaletti  G. Chemotherapy -induced  peripheral  
neurotoxicity  (CIPN):  an update.  Crit. Rev. Oncol.  Hematol.  2012  Apr;82(1):51 –77.  
38. Zulian i V, Rivara  M, Fantini  M, Costantino  G. Sodium  channel  blockers  for 
neuropathic  pain.  Expert  Opin  Ther Pat. 2010  Jun;20(6):755 –79.  
39. Erdoğan  C, Yücel  M, Akgü n H, Kaşkç T, Semai  Bek V, Gökçil Z. Effects  of topiramate  
on peripheral  nerve  excitability.  J Clin Neurophysiol.  2012  Jun;29(3):268 –70.  
40. Smith  SC, Lamping  DL, Maclaine  GDH.  Measuring  health -related  quality  of life in 
diabetic  peripheral  neuropathy:  a systematic  review.  Diabetes  Res. Clin. Pract.  2012  
Jun; 96(3):261 –70.  
41. Coelho  T, Maia  LF, Martins  da Silva  A, Waddington  Cruz  M, Planté -Bordeneuve  V, 
Lozeron  P, et al. Tafamidis  for transthyretin  familial  amyloid  polyneuropathy:  A 
randomized,  controlled  trial. Neurology.  2012  Aug 21;79(8):785 –92. PMCID:  
PMC4098875  
42. Shun  CT, Chang  YC, Wu HP, Hsieh  SC, Lin WM, Lin YH, et al. Skin denervation  in 
type 2 diabetes:  correlations  with diabetic  duration  and functional  impairments.  Brain.  
2004  ed. 2004  Jul;127(Pt  7):1593 –605.  
43. Periquet  MI, Novak  V, Collins  MP, Nagaraja  HN, Erdem  S, Nash  SM, et al. Painful  
sensory  neuropathy  prospective  evaluation  using  skin biopsy.  Neurology.  1999;  
53:1641 –7.  
44. Smith  AG, Tripp  C, Singleton  JR. Skin biopsy  findings  in patients  with neuropathy  
associated  with diabetes  and impaired  glucose  toleran ce. Neurology.  2001;  57:1701.   
45. Tesfaye  S, Boulton  AJ, Dyck  PJ, Freeman  R, Horowitz  M, Kempler  P, et al. Diabetic  
neuropathies:  update  on definitions,  diagnostic  criteria,  estimation  of severity,  and 
treatments.  Diabetes  Care.  2010  ed. 2010  Oct;33(10):2 285–93. PMCID:  
PMC2945176  
46. The Expert  Panel  on Detection  EATOHBCIA.  The Third  Report  of the ATP III. 
National  Institutes  of Health  National  Heart  Lung  and Blood  Institute,  Bethesda  
Maryland.  2001;  NIH publication  01-3670:  https://www.nhlbi.nih.gov –guide lines–
cholesterol –index.htm.   
47. England  JD, Gronseth  GS, Franklin  G, Carter  GT, Kinsella  LJ, Cohen  JA, et al. 
Practice  Parameter:  evaluation  of distal  symmetric  polyneuropathy:  role of laboratory  
and genetic  testing  (an evidence -based  review).  Report  of the American  Academy  of 
Neurology,  American  Association  of Neuromuscular  and Electrodiagnostic  Medicine,  
and American  Academy  of Physical  Medicine  and Rehabilitation.  Neurology.  2008  
ed. 2009  Jan 13;72(2):185 –92.  
48. Singleton  JR, Bixby  B, Russell  JW, Feldman  EL, Peltier  A, Goldstein  J, et al. The 
Utah  Early  Neuropathy  Scale:  a sensitive  clinical  scale  for early  sensory  predominant  
neuropathy.  Journal  of the Peripheral  nervous  system : JPNS.  2008  ed. Blackwell  
Publishing  Inc; 2008  Sep;13(3):218 –27.  
49. Osm an A, Bagge  CL, Gutierrez  PM, Konick  LC, Kopper  BA, Barrios  FX. The Suicidal  
Behaviors  Questionnaire -Revised  (SBQ -R): validation  with clinical  and nonclinical  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  63 of 67 samples.  Assessment.  2001  Dec;8(4):443 –54.  
50. England  JD, Gronseth  GS, Franklin  G, Miller  RG, Asbury  AK, Carter  GT, et al. Distal  
symmetric  polyneuropathy:  a definition  for clinical  research:  report  of the American  
Academy  of Neurology,  the American  Association  of Electrodiagnostic  Medicine,  and 
the American  Academy  of Physical  Medicine  and Rehabili tation.  Neurology.  2005  
Jan 25;64(2):199 –207.  
51. Bril V, Ellison  R, Ngo M, Bergstrom  B, Raynard  D, Gin H. Electrophysiological  
monitoring  in clinical  trials.  Roche  Neuropathy  Study  Group.  Muscle  Nerve.  1998  
Nov;21(11):1368 –73.  
52. Lauria  G, Bakkers  M, Schmitz  C, Lombardi  R, Penza  P, Devigili  G, et al. 
Intraepidermal  nerve  fiber density  at the distal  leg: a worldwide  normative  reference  
study.  Journal  of the Peripheral  nervous  system : JPNS.  2010  ed. 2010  
Sep;15(3):202 –7.  
53. Bastyr  EJ, Price  KL, Bril V, MBBQ  Study  Group.  Development  and validity  testing  of 
the neuropathy  total symptom  score -6: questionnaire  for the study  of sensory  
symptoms  of diabetic  peripheral  neuropathy.  Clin Ther.  2005  Aug;27(8):1278 –94.  
54. Zelman  DC, Gore  M, Dukes  E, Tai K-S, Bran denburg  N. Validation  of a modified  
version  of the brief pain inventory  for painful  diabetic  peripheral  neuropathy.  J Pain 
Symptom  Manage.  2005  Apr;29(4):401 –10.  
55. Cleeland  CS, Ryan  KM. Pain assessment:  global  use of the Brief Pain Inventory.  
Ann. Acad.  Med.  Singap.  1994  Mar; 23(2):129 –38.  
56. Beriault  K, Carpentier  AC, Gagnon  C, Menard  J, Baillargeon  J-P, Ardilouze  J-L, et al. 
Reproducibility  of the 6-minute  walk test in obese  adults.  Int J Sports  Med.  2009  
Oct;30(10):725 –7.  
57. Tuttle  LJ, Sinacore  DR, Mueller  MJ. Intermuscular  adipose  tissue  is muscle  specific  
and associated  with poor functional  performance.  J Aging  Res. 2012;  2012:172957.  
PMCID:  PMC3361226  
58. Herman  T, Giladi  N, Hausdorff  JM. Properties  of the “timed  up and go” test: more  
than meets  the eye. Gerontology.  2011;57(3):203 –10. PMCID:  PMC3094679  
59. Vaz MM, Costa  GC, Reis JG, Junior  WM, Albuquerque  de Paula  FJ, Abreu  DC. 
Postural  control  and functional  strength  in patients  with type 2 diabetes  mellitus  with 
and without  peripheral  neuropathy.  Arch Phys  Med Rehabil.  2013  Dec;94(12):2465 –
70.  
60. Jernigan  SD, Pohl PS, Mahnken  JD, Kluding  PM. Diagnostic  accuracy  of fall risk 
assessment  tools  in people  with diabetic  peripheral  neuropathy.  Phys  Ther.  2012  
Nov;92(11):1461 –70. PMCID:  PMC3488267    
62. Lauria  G, Hsieh  ST, Johansson  O, Kennedy  WR, Leger  JM, Mellgren  SI, et al. 
European  Federation  of Neurological  Societies/Peripheral  Nerve Society  Guideline  
on the use of skin biopsy  in the diagnosis  of small  fiber neuropathy.  Report  of a joint 
task force  of the European  Federation  of Neurological  Societies  and the Peripheral  
Nerve  Society.  Eur J Neurol.  2010  ed. 2010  Jul;17(7):903 –12–e44–9.  
63. Dyck  PJ, Oviatt  KF, Lambert  EH. Intensive  evaluation  of referred  unclassified  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  64 of 67 neuropathies  yields  improved  diagnosis.  Ann. Neurol.  1981;  10:222 –6.  
64. Thienel  U, Neto  W, Schwabe  SK, Vijapurkar  U, Topiramate  Diabetic  Neuropathic  
Pain Study  Group.  Topiramate  in painful  diabetic  polyneuropathy:  findings  from three  
double -blind  placebo -controlled  trials.  Acta Neurol.  Scand.  2004  Oct;110(4):221 –31.  
65. Linde  M, Mulleners  WM, Chronicle  EP, McCrory  DC. Topiramate  for the prophylaxis  
of episodic  migrain e in adults.  Cochrane  Database  Syst Rev. John  Wiley  & Sons,  
Ltd; 2013;6:CD010610.   
66. Dyck  PJ, Norell  JE, Tritschler  H, Schuette  K, Samigullin  R, Ziegler  D, et al. 
Challenges  in design  of multicenter  trials:  end points  assessed  longitudinally  for 
change  and monotonicity.  Diabetes  Care.  2007  ed. 2007  Oct;30(10):2619 –25.  
67. Dyck  P, OBrien  P. Meaningful  degrees  of prevention  or improvement  of nerve  
conduction  in controlled  clnical  trials  of diabetic  neuropathy.  Diabetes  Care.  1989;  
12:649 –52.  
68. Griffin  JW, Thompson  WJ. Biology  and pathology  of nonmyelinating  Schwann  cells.  
Glia. 2008  Nov 1;56(14):1518 –31.  
69. Smith  AG, Howard  JR, Kroll R, Ramachandran  P, Hauer  P, Singleton  JR, et al. The 
reliability  of skin biopsy  with measurement  of intraepidermal  nerve  fiber density.  J. 
Neurol.  Sci. 2005  Jan 15;228(1):65 –9.  
70. Rajan  B, Polydefkis  M, Hauer  P, Griffin  JW, McArthur  JC. Epidermal  reinnervation  
after intracutaneous  axotomy  in man.  J Comp  Neurol.  2003  Feb 24;457(1):24 –36.  
71. Polydefkis  M, Hauer  P, Sheth  S, Sirdofsky  M, Griffin  JW, McArthur  JC. The time 
course  of epidermal  nerve  fibre regeneration:  studies  in normal  controls  and in people  
with diabetes,  with and without  neuropathy.  Brain.  2004  Jul;127(Pt  7):1606 –15.  
72. Cornblath  DR, Chaudhry  V, Carter  K, Lee D, Seysedadr  M, Miernicki  M, et al. Total  
neuropathy  score:  validation  and reliability  study.  Neurology.  1999  Nov 
10;53(8):1660 –4.  
73. Muniyappa  R, Lee S, Chen  H, Quon  MJ. Current  approaches  for assessing  insulin  
sensitivity  and resistance  in vivo: advantages,  limitations,  and appropriate  usage.  
Am. J. Physiol.  Endocrinol.  Metab.  2008  Jan; 294(1):E15 –26.  
74. Goodman  SN. Multiple  Comparisons,  Explained.  Am. J. Epidemiol.  Oxford  University  
Press;  1998  May 1;147(9):807 –12.  
75. SAS/STAT  13.2 User's  Guide .  
76. Molenberghs  G, Thijs  H, Jansen  I, Beunckens  C, Kenward  MG, Mallinckrodt  C, et al. 
Analyzing  incomplete  longitudinal  clinical  trial data.  Biostatistics.  Oxford  University  
Press;  2004  Jul;5(3):445 –64.  
77. Fitzmaurice  GM, Laird  NM, Ware  JH. Applied  Longitudinal  Analysis.  John  Wiley  & 
Sons;  2012.   
78. Verbeke  G, Molenberghs  G. Linear  Mixed  Models  for Longitudinal  Data.  Springer  
Science  & Business  Media;  2009.   
79. Littell  RC, Pendergast  J, Natarajan  R. Modelling  covariance  structure  in the analysis  
of repeated  measures  data.  Stat Med.  2000  Jul 15;19(13):1793 –819.  
80. Kincaid  C. Guidelines  for selecting  the covariance  structure  in mixed  model  analysis,  
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  65 of 67 paper  198-30 in Proceedings  of the Thirtieth  Annual  SAS Users  Group  …. Inc; 2005.   
81. Verbeke  G, Molen berghs  G. Linear  Mixed  Models  for Longitudinal  Data.  Springer;  
2000.   
82. Multiple  imputation:  a primer.   
83. Schafer  JL. Multiple  imputation:  a primer.  Stat Methods  Med Res. SAGE  
Publications;  1999  Mar;8(1):3 –15.  
84. Freedman  LS, Graubard  BI, Schatzkin  A. Statistical  validation  of intermediate  
endpoints  for chronic  diseases.  Stat Med.  1992  Jan 30;11(2):167 –78.  
85. Rubin  DE. Direct  and indirect  causal  effects  via potential  outcomes.  Scan  J Statistics.  
32:161 –70.  
86. Frangakis  CE, Rubin  DB. Principal  stratification  in causal  inference.  Biometrics.  2002  
Mar;58(1):21 –9. PMCID:  PMC4137767  
87. Joffe  MM, Greene  T. Related  causal  frameworks  for surrogate  outcomes.  Biometrics.  
Blackwell  Publishing  Inc; 2009  Jun;65(2):530 –8.  
88. SAS Institute  Inc. SAS/STAT  13.2 User's  Guide.   
89.  Myers,  A. M., Fletcher,  P. C., Myers,  A. H., & Sherk,  W. (1998).  Discriminative  and  
evaluative  properties  of the activities -specific  balance  confidenc e (ABC)  scale.  J 
Gerontol  a Biol Sci Med Sci, 53(4), M287 –94. 
90.  Topolski,  T. D., LoGerfo,  J., Patrick,  D. L., Williams,  B., Walwick,  J., & Patrick,  M. B. 
(2006).  The Rapid  Assessment  of Physical  Activity  (RAPA)  among  older  adults.  
Preventing  Chronic  Disease , 3(4), A118.  
 
 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  66 of 67 15. Appendix  A  
Schedule  of Assessments:   Topiramate  as a Disease  Modifying  Therapy  for CSPN  
Tests and Evaluations1 Screening  Baseline  W16  W32 W48  W64  W80  W96  Safety 
Assessment  Early 
Termination  
Visit Number  1 2 3 4 5 6 7 8 9 ET 
Telephone Calls  2  X²  X² X² X² X² X²    
Informed Consent  X                   
Inclusion/exclusion criteria  X X                 
Medical History  X                   
Complete Physical Examination  X              X X   X 
Abbreviation physical Examination  
(including visual field and fall risk 
assessment)    X X X X X X    
Interval Medical History    X X X X X X X X X 
Vital Signs (including height3, weight, and 
BMI)  X X X X X X X X X X 
Waist Circumference  X  X X X X X X X X 
Nerve Conduction Studies   X    X   X   X   X 
Distal Thigh Skin Biopsy    X   X   X   X   X 
Topiramate Level   X  X  X  X  X 
Serum B12 and  immunofixation  X          
Fasting glucose4, insulin, and lipid panel, 
and hemoglobin A1c  X     X   X   X   X 
2-HR o ral glucose tolerance test  X     X   X   X   X 
Basic metabolic p anel and complete blood 
count  X X X X X X X X X X 
Serum pregnancy test  X   X X X X X       
                                                 
1 Baseline visit will occur within 30 days of screening. All follow -up visits  must occur within ± 7 days.  
2 Study  coordinators  will call each subject  at least once  per month  to encourage  participation  and minimize  dropout  risk. 
3 Height  at screening  visit only.  
4 Fasting  glucose  is the pre-glucola/dextrose  sample  for the OGTT  (gray  top) . 
 
NN108  Topiramate  as a Disease  Modifying  Therapy  for CSPN   
Version  8.0  
Version  date 8/8/2018  
Page  67 of 67 Urine pregnancy test    X                 
Functional and mobility testing (6MWT, 
TUG, ABC Scale )   X   X   X   X   X 
Randomization    X                 
Study drug dispensing    X X X X X X       
Study drug reconciliation      X X X X X X   X  
Neuropathy symptom scales (NTSS -6, BPI -
DN)   X X X X X X X  X 
NQOL -DN X  X X X X X X  X 
UENS  X  X X X X X X  X 
C-SSRS  X X X X X X X X X X 
RAPA   X  X  X  X  X 
Concomitant medications  X X X X X X X X X X 
Adverse event review   X5 X X X X X X X X X 
ECG X          
DNA sample    X                 
 
 
 
                                                 
5 AEs to be collected  at screening  only for events  related  to study  procedures  (e.g.,  skin biopsy)  